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Abstract 
Improving the reproducibility of biomedical research is a major challenge. Transparent and accurate reporting are 
vital to this process; it allows readers to assess the reliability of the findings, and repeat or build upon the work of 
other researchers. The NC3Rs developed the ARRIVE guidelines in 2010 to help authors and journals identify the 
minimum information necessary to report in publications describing in vivo experiments.  
Despite widespread endorsement by the scientific community, the impact of the ARRIVE guidelines on the 
transparency of reporting in animal research publications has been limited. We have revised the ARRIVE 
guidelines to update them and facilitate their use in practice. The revised guidelines are published alongside this 
paper. This Explanation and Elaboration document was developed as part of the revision. It provides further 
information about each of the 21 items in ARRIVE 2019, including the rationale and supporting evidence for their 
inclusion in the guidelines, elaboration of details to report, and examples of good reporting from the published 
literature.  
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Introduction 
Transparent and accurate reporting is essential to improve the reproducibility of scientific research; it enables 
others to scrutinise the methodological rigour of the studies, assess how reliable the findings are, and repeat or 
build upon the work. 
However, evidence shows that the majority of publications fail to include key information and there is significant 
scope to improve the reporting of studies involving animal research [1-4]. To that end, the NC3Rs published the 
ARRIVE guidelines in 2010. The guidelines are a checklist of information to include in a manuscript to ensure that 
publications contain enough information to add to the knowledge base [5]. The guidelines have received 
widespread endorsement from the scientific community and are currently recommended by more than a thousand 
journals, with further endorsement from research funders, universities and learned societies worldwide. 
Studies measuring the impact of ARRIVE on the quality of reporting have produced mixed results [6-11] and there 
is evidence that in vivo scientists are not sufficiently aware of the importance of reporting the information covered in 
the guidelines, and fail to appreciate the relevance to their work or their research field [12].  
As a new international working group – the authors of this publication, we have revised the guidelines to update 
them and facilitate their uptake; the ARRIVE guidelines 2019 are published alongside this paper [13]. We have 
updated the recommendations in line with current best practice, reorganised the information and classified the 
items into two sets. The ARRIVE Essential 10 constitute the minimum reporting requirement and the 
Recommended Set provides further context to the study described. The two sets help authors, journal staff, editors 
and reviewers use the guidelines in practice, and allow a pragmatic implementation with an initial focus on the most 
critical issues. Once the Essential 10 are consistently reported in manuscripts, items from the Recommended Set 
can be added to journal requirements over time until all 21 items are routinely reported in all manuscripts. Full 
methodology for the revision and the allocation of items into sets is described in the accompanying publication [13]. 
A key aspect of the revision was to develop this Explanation and Elaboration document to provide background and 
rationale for each of the 21 items of ARRIVE 2019. Here we present additional guidance for each item and 
subitem, explain the importance of reporting this information in manuscripts that describe animal research, 
elaborate on what to report, and provide supporting evidence. Each subitem is also illustrated with examples of 
good reporting from the published literature.  
 
Box 1: Glossary 
Bias: Introduction of a systematic error in the estimated effect of an intervention, caused by inadequacies in the 
design, conduct, or analysis of an experiment. 
Effect size: Quantitative measure that estimates the magnitude of differences between groups, or relationships 
between variables. 
Experimental unit: Biological entity subjected to an intervention independently of all other units, such that it is 
possible to assign any two experimental units to different treatment groups. 
External validity: Extent to which the results of an animal experiment provide a correct basis for generalisations 
to other populations of animals (including humans) and/or other environmental conditions. 
False positive: Statistically significant result obtained by chance when the effect being investigated does not 
exist. 
False negative: Non-statistically significant result obtained when the effect being investigated genuinely exists. 
Independent variable of interest: Factor that a researcher manipulates within a controlled environment in order 
to test its impact on the outcome measured. Also known as: predictor variable, factor of interest. 
Internal validity: Refers to the rigour of the study design and statistical analysis to isolate cause and effect, and 
attribute the effect observed to manipulation of the independent variable of interest. In an experiment with high 
internal validity, sources of bias and chance observations are minimised. In an experiment with low internal 
validity, the effect may be caused by bias, chance and other nuisance variables rather than the independent 
variable(s) of interest. 
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Null and alternative hypotheses: The null hypothesis (H0) refers to the postulate that the response being 
measured is unaffected by the experimental manipulation being tested. The alternative hypothesis (H1) refers to 
the postulate that manipulating the independent variable of interest has an effect on the response measured. 
Nuisance variable: Sources of variability or conditions that could potentially bias results. Also known as: 
confounding factor, confounding variable 
Outcome measure: Any variable recorded during a study to assess the effects of a treatment or experimental 
intervention. Also known as: dependent variable, response variable 
Power: Probability that a test of significance will detect an effect (i.e. a deviation from the null hypothesis), if an 
effect exists (i.e. true positive result). 
Sample size: Number of experimental units per group, also referred to as N number. 
Definitions adapted from [14, 15] and placed in the context of animal research. 
 
1. ARRIVE Essential 10 
The ARRIVE Essential 10 (Box 2) constitute the minimum reporting requirement, to ensure that reviewers and 
readers can assess the reliability of the findings presented. There is no ranking within the set, items are presented 
in a logical order. 
Box 2: ARRIVE Essential 10 
1. Study design 
2. Sample size 
3. Inclusion and exclusion criteria 
4. Randomisation 
5. Blinding 
6. Outcome measures 
7. Statistical methods 
8. Experimental animals 
9. Experimental procedures  
10. Results 
 
Item 1. Study design 
For each experiment, provide brief details of study design including: 
1a. The groups being compared, including control groups. If no control group has been used, the 
rationale should be stated. 
Explanation  
The choice of control or comparator group is dependent on the experimental objective. Negative controls are used 
to determine if a difference between groups is caused by the intervention (e.g. wild-type animals vs genetically 
modified animals, placebo vs active treatment, sham surgery vs surgical intervention). Positive controls can be 
used to support the interpretation of negative results or determine if an expected effect is detectable.  
It may not be necessary to include a separate control with no active treatment if, for example, the experiment aims 
to compare a treatment administered by different methods (e.g. intraperitoneal administration vs. oral gavage), or 
animals that are used as their own control in a longitudinal study. A pilot study, such as one designed to test the 
feasibility of a procedure might also not require a control group.  
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For complex study designs, a visual representation is more easily interpreted than a text description, so a timeline 
diagram or flow chart is recommended. Diagrams facilitate the identification of which treatments and procedures 
were applied to specific animals or groups of animals, and at what point in the study these were performed. They 
also help to communicate complex design features such as clustering or nesting (hierarchical designs), blocking (to 
reduce unwanted variation, see item 4 – Randomisation), or repeated measurements over time on the same 
experimental unit (repeated measures designs) [16, 17]. The Experimental Design Assistant (EDA) is a platform to 
support researchers in the design of in vivo experiments, it can be used to generate diagrams to represent any type 
of experimental design [18].  
Report the groups clearly so that test groups, comparators and controls (negative or positive) can be identified 
easily. State clearly if the same control group was used for multiple experiments. 
Examples 
1) “The DAV1 study is a one-way, two-period crossover trial with 16 piglets receiving amoxicillin and placebo at 
period 1 and only amoxicillin at period 2. Amoxicillin was administered orally with a single dose of 30 mg.kg-1. 
Plasma amoxicillin concentrations were collected at same sampling times at each period: 0.5, 1, 1.5, 2, 4, 6, 8, 
10 and 12 h.” [19] 
2) “Figure A: Example of a study plan created using the Experimental Design Assistant showing a simple 
comparative study for the effect of two drugs on the metastatic spread of two different cancer cell lines. Block 
randomisation has been used to create 3 groups containing an equal number of zebrafish embryos injected with 
either cell line, and each group will be treated with a different drug treatment (including vehicle control). Each 
measurement outcome will be analysed by 2-way ANOVA to determine the effect of drug treatment on growth, 
survival and invasion of each cancer cell line.” [20] 
 
 
1b. The experimental unit (e.g. a single animal, litter, or cage of animals). 
Explanation 
The experimental unit is the biological entity subjected to an intervention independently of all other units, such that 
it is possible to assign any two experimental units to different treatment groups. The sample size is the number of 
experimental units per group. 
Clearly indicate the experimental unit for each experiment so that the sample sizes and statistical analyses can be 
properly evaluated. There is a risk that if the experimental unit is not correctly identified, the sample size used in 
the data analysis will be incorrect. Inflation of the sample size by conflating experimental units with subsamples or 
repeated measurements is known as ‘pseudoreplication’. This may invalidate the analysis and resulting 
conclusions [21, 22] (see also item 7 – Statistical methods). 
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Commonly, the experimental unit is the individual animal, each independently allocated to a treatment group (e.g. a 
drug administered by injection). However, the experimental unit may be the cage or the litter (e.g. a diet 
administered to a whole cage, or a treatment administered to a dam and investigated in her pups), or it could be 
part of the animal (e.g. different drug treatments applied topically to distinct body regions of the same animal). 
Animals may also serve as their own controls receiving different treatments separated by washout periods; here 
the experimental unit is an animal for a period of time. There may also be multiple experimental units in a single 
experiment, such as when a treatment such as diet is given to a pregnant dam and then the weaned pups are 
allocated to different diets [23]. See [24-26] for further guidance on identifying experimental units.  
Examples  
1) “The present study used the tissues collected at E15.5 from dams fed the 1X choline and 4X choline diets (n 
= 3 dams per group, per fetal sex; total n = 12 dams). To ensure statistical independence, only one placenta 
(either male or female) from each dam was used for each experiment. Each placenta, therefore, was considered 
to be an experimental unit.” [27] 
2) “We have used data collected from high-throughput phenotyping, which is based on a pipeline concept where 
a mouse is characterized by a series of standardized and validated tests underpinned by standard operating 
procedures (SOPs)…. The individual mouse was considered the experimental unit within the studies.” [28] 
3) “Fish were divided in two groups according to weight (0.7-1.2 g and 1.3-1.7 g) and randomly stocked (at a 
density of 15 fish per experimental unit) in 24 plastic tanks holding 60 L of water.” [29] 
4) “In the study, n refers to number of animals, with five acquisitions from each [corticostriatal] slice, with a 
maximum of three slices obtained from each experimental animal used for each protocol (six animals each 
group).” [30] 
  
Item 2. Sample size 
2a. Specify the exact number of experimental units allocated to each group, and the total number in each 
experiment. Also indicate the total number of animals used. 
Explanation 
Sample size relates to the number of experimental units in each group at the start of the study, and is usually 
represented by N (See item 1 - Study design for further guidance on identifying and reporting experimental units). 
This information is crucial to assess the validity of the statistical model and the robustness of the experimental 
results.  
Report the exact value of N per group and the total number in each experiment. If the experimental unit is not the 
animal, also report the total number of animals to help readers understand the study design. For example, in a 
study investigating diet using cages of animals housed in pairs, the number of animals is double the number of 
experimental units. Reporting the total number of animals is also useful to identify if any were re-used between 
experiments.  
Example 
1) “Dams (for n see Table …) were assigned to treatments in a manner that provided similar means and 
variances in body weight before dosing was initiated…. For statistical purposes, the numbers/group are the 
number of litters, not the number of pups.” [31]  
Maternal and Neonatal Pup Effects of Various Phthalate Esters (PE) after Perinatal Maternal Exposure (GD 14–PND 3) to 
0.75 g PE/kg/day on the Sprague-Dawley Rat 
 
 Control BBP DEHP DINP DEP DMP DOTP  
Numbers of dams 
assigned to this study 
Block 1/Block 2  
9/10 5/8 7/9 6/8 5/0 5/0 0/8 
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Numbers of dams died  0 0 0 0 2 1 0  
Numbers of dams with 
live pups at day 2  
19 13 16 14 3 4 8 
 
Numbers of dams with 
live pups at weaning  
19 11 16 14 3 4 8 [31] 
 
 
2b. Explain how the sample size was decided. Provide details of any a priori sample size calculation, if 
done.   
Explanation  
For any type of experiment, it is crucial to explain how the sample size was determined. For hypothesis-testing 
experiments, where inferential statistics are used to estimate the size of the effect and to determine the weight of 
evidence against the null hypothesis, the sample size needs to be justified to ensure experiments are of an optimal 
size to test the research question [32, 33] (see item 13 – Objectives). Power is the probability that a test of 
significance will detect an effect (i.e. a deviation from the null hypothesis), when the effect being investigated 
genuinely exists (i.e. true positive result). Sample sizes that are too small (i.e. underpowered studies) produce 
inconclusive results, whereas sample sizes that are too large (i.e. overpowered studies) raise ethical issues over 
unnecessary use of animals and may produce trivial findings that are statistically significant but not biologically 
relevant [34]. Low power has three effects: first, within the experiment, real effects are more likely to be missed; 
second, where an effect is detected, this will often be an over-estimation of the true effect size [25]; and finally, 
when low power is combined with publication bias, there is an increase in the false positive rate in the published 
literature [35]. Consequently, low powered studies contribute to the poor internal validity of research and risk 
wasting animals used in inconclusive research [36].  
Study design can influence the statistical power of an experiment. Split-plot designs [37], factorial designs [38], or 
group-sequential designs [39] can increase the power of a study for a given number of animals. Statistical 
programs to help perform a priori sample size calculations exist for a variety of experimental designs and statistical 
analyses, for example G*power [40].  Choosing the appropriate calculator or algorithm to use depends on the type 
of outcome measures and independent variables, and the number of groups. Consultation with a statistician is 
recommended, especially when the experimental design is complex or unusual. 
Where the experiment tests the effect of an intervention on the mean of a continuous outcome measure, the 
sample size can be calculated a priori, based on a mathematical relationship between the desired effect size, 
variability estimated from prior data, chosen significance level, power and sample size (See Box 3, and [24, 41] for 
practical advice). For an a priori sample size determination, report the analysis method (e.g. two-tailed student’s t-
test with a 0.05 significance threshold), the effect size of interest and a justification explaining why this effect size is 
relevant, the estimate of variability used (e.g. standard deviation) and how it was estimated, and the power 
selected. 
 Box 3: Information used in a power calculation 
Sample size calculation is based on a mathematical relationship between the following parameters: effect size, 
variability, significance level, power and sample size. Questions to consider are:  
The primary objective of the experiment – what is the main outcome measure? 
The primary outcome measure should be identified in the planning stage of the experiment; it is the outcome of 
greatest importance, which will answer the main experimental question. 
What is a biologically or clinically relevant effect size?  
The effect size is the minimum change in the primary outcome measure between the groups under study, which 
would be of interest biologically and would be worth taking forward into further work. 
What is the estimate of variability? 
Estimates of variability can be obtained: 
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▪ From data collected from a preliminary experiment conducted under identical conditions to the planned 
experiment, e.g. a previous experiment in the same lab, testing the same treatment, under similar conditions, 
on animals with the same characteristics.  
▪ From the control group in a previous experiment testing a different treatment. 
▪ From a similar experiment reported in the literature. 
What risk of a false positive is acceptable? (significance threshold) 
The significance level or threshold (α) is the probability of obtaining a significant result by chance (a false 
positive) when the null hypothesis is true (i.e. there is no real, biologically relevant difference between the 
groups). If it is set at 0.05 then the risk of obtaining a false positive is 1 in 20 for a single statistical test. However, 
the threshold or the p values will need to be adjusted in scenarios of multiple testing (e.g. by using a Bonferroni 
correction). 
What risk of a false negative is acceptable? (power) 
The power (1-β) is the probability that the experiment will correctly lead to the rejection of the null hypothesis if 
the effect being investigated genuinely exists (i.e. detect that there is a biologically meaningful difference when 
there is one). A target power between 80-95% is normally deemed acceptable. 
Will you use a one or two-sided test? (directionality) 
The directionality of a test depends on the distribution of the test statistics for a given analysis. For tests based 
on t or z distributions (such as t-tests), whether the data will be analysed using a one or two-sided test relates to 
whether the alternative hypothesis (H1) is directional or not. An experiment with a directional (one-sided) H1 can 
be powered and analysed with a one-sided test. This assumes that direction of the effect is known (this is very 
rare in biology) and the goal is to maximise the chances of detecting this effect. However, the investigator cannot 
then test for the possibility of missing an effect in the untested direction. Choosing a one-tailed test for the sole 
purpose of attaining statistical significance is not appropriate.   
Two-sided tests with a non-directional H1 are much more common and allow researchers to detect the effect of a 
treatment regardless of its direction.  
Note that analyses such as ANOVA and chi-square are based on asymmetrical distributions (F- distribution and 
chi-square distribution) with only one tail. Therefore, these tests do not have a directionality option. 
 
There are several types of studies where a priori sample size calculations are not appropriate. For example, the 
number of animals needed for antibody or tissue production is determined by the amount required and the 
production ability of an individual animal. For studies where the outcome is a successful generation of a sample or 
a condition (e.g. the production of transgenic animals), the number of animals is determined by the probability of 
success of the experimental procedure.  
In early feasibility or pilot studies, the number of animals required depends on the purpose of the study. Where the 
objective of the preliminary study is to improve procedures and equipment, the number of animals needed is 
generally small. In such cases power calculations are not appropriate and sample sizes can be estimated based on 
operational capacity and constraints [42]. Pilot studies alone are unlikely to provide adequate data on variability for 
a power calculation for future experiments. Systematic reviews and previous studies are more appropriate sources 
of information on variability [43].  
Regardless of whether a power calculation was used or not, when explaining how the sample size was determined 
take into consideration any anticipated loss of animals or data, for example due to exclusion criteria established 
upfront or expected attrition (see item 3 – inclusion and exclusion criteria). 
Examples 
1) “The sample size calculation was based on postoperative pain numerical rating scale (NRS) scores after 
administration of buprenorphine (NRS AUC mean = 2.70; noninferiority limit = 0.54; standard deviation = 0.66) as 
the reference treatment and also Glasgow Composite Pain Scale (GCPS) scores using online software 
(Experimental design assistant; https://eda.nc3rs.org.uk/eda/login/auth). The power of the experiment was set to 
80%. A total of 20 dogs per group were considered necessary.” [44] 
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2) “We selected a small sample size because the bioglass prototype was evaluated in vivo for the first time in the 
present study, and therefore, the initial intention was to gather basic evidence regarding the use of this biomaterial 
in more complex experimental designs.” [45] 
 
Item 3. Inclusion and exclusion criteria 
3a. Describe any criteria established a priori for including or excluding animals (or experimental units) 
during the experiment, and data points during the analysis. 
Explanation  
Inclusion and exclusion criteria define the eligibility or disqualification of animals and data once the study has 
commenced. To ensure scientific rigour, the criteria should be defined before the experiment starts and data are 
collected [46]. Inclusion criteria should not be confused with animal characteristics (see item 8 – Experimental 
animals) but can be related to these (e.g. body weights must be within a certain range for a particular procedure) 
or related to other study parameters (e.g. task performance has to exceed a given threshold). Exclusion criteria 
may result from technical or welfare issues such as complications anticipated during surgery, or circumstances 
where test procedures might be compromised (e.g. development of motor impairments that could affect 
behavioural measurements). Criteria for excluding samples or data include failure to meet quality control standards, 
such as insufficient sample volumes, unacceptable levels of contaminants, poor histological quality, etc. Similarly, 
how the researcher will define and handle data outliers during the analysis should be also decided before the 
experiment starts (see subitem 3b for guidance on responsible data cleaning). 
Exclusion criteria may also reflect the ethical principles of a study in line with its humane endpoints (see item 16 – 
Animal care and monitoring). For example, in cancer studies an animal might be dropped from the study and 
euthanised before the predetermined time point if the size of a subcutaneous tumour exceeds a specific volume 
[47]. If losses are anticipated, these should be considered when determining the number of animals to include in 
the study (see item 2 – Sample size).  
Best practice is to include all a priori inclusion and exclusion/outlier criteria in a pre-registered protocol (see item 19 
– Protocol registration). At the very least these criteria should be documented in a lab notebook and reported in 
manuscripts, explicitly stating that the criteria were defined before any data was collected. 
Example  
1) “The animals were included in the study if they underwent successful MCA occlusion (MCAo), defined by a 60% 
or greater drop in cerebral blood flow seen with laser Doppler flowmetry. The animals were excluded if insertion of 
the thread resulted in perforation of the vessel wall (determined by the presence of sub-arachnoid blood at the 
time of sacrifice), if the silicon tip of the thread became dislodged during withdrawal, or if the animal died 
prematurely, preventing the collection of behavioral and histological data.” [48] 
 
3b. For each experimental group, report any animals, experimental units or data points not included in 
the analysis and explain why. 
Explanation  
Animals, experimental units, or data points that are unaccounted for can lead to instances where conclusions 
cannot be supported by the raw data [49]. Reporting exclusions and attritions provides valuable information to other 
investigators evaluating the results, or who intend to repeat the experiment or test the intervention in other species. 
It may also provide important safety information for human trials (e.g. exclusions related to adverse effects).  
There are many legitimate reasons for experimental attrition, some of which are anticipated and controlled for in 
advance (see subitem 3a on defining exclusion and inclusion criteria) but some data loss might not be anticipated. 
For example, data points may be excluded from analyses due to an animal receiving the wrong treatment, 
unexpected drug toxicity, infections or diseases unrelated to the experiment, sampling errors (e.g. a malfunctioning 
assay that produced a spurious result, inadequate calibration of equipment), or other human error (e.g. forgetting to 
switch on equipment for a recording).  
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In some instances, it may be scientifically justifiable to remove outlier data points from an analysis, such as 
readings that are outside a plausible range. Providing the reasoning for removing data points enables the 
distinction to be made between responsible data cleaning and data manipulation. When reasons are not disclosed 
the reliability of the conclusions is in question, as inappropriate data cleaning has the potential to bias study 
outcomes [50].  
There is a movement towards greater data sharing (see item 20 – Data access), along with an increase in 
strategies such as code sharing to enable analysis replication. These practices, however transparent, still need to 
be accompanied by a disclosure on the reasoning for data cleaning, and whether it was pre-defined. 
Report all animal exclusions and loss of data points, along with the rationale for their exclusion. Accompanying 
these criteria should be an explicit description of whether researchers were blinded to the group allocations when 
data or animals were excluded (see item 5 – Blinding and [51]), and whether these criteria were decided prior to 
the experiment [8, 32, 52]. Explicitly state where built-in models in statistics packages have been used to remove 
outliers (e.g. GraphPad Prism’s outlier test). 
Examples 
1) “Pen was the experimental unit for all data. One entire pen (ZnAA90) was removed as an outlier from both Pre-
RAC and RAC periods for poor performance caused by illness unrelated to treatment.... Outliers were determined 
using Cook’s D statistic and removed if Cook’s D > 0.5. One steer was determined to be an outlier for day 48 liver 
biopsy TM and data were removed.” [53] 
2) “Seventy-two SHRs were randomized into the study, of which 13 did not meet our inclusion and exclusion 
criteria because the drop in cerebral blood flow at occlusion did not reach 60% (seven animals), postoperative 
death (one animal: autopsy unable to identify the cause of death), haemorrhage during thread insertion (one 
animal), and disconnection of the silicon tip of the thread during withdrawal, making the permanence of 
reperfusion uncertain (four animals). A total of 59 animals were therefore included in the analysis of infarct volume 
in this study. In error, three animals were sacrificed before their final assessment of neurobehavioral score: one 
from the normothermia/water group and two from the hypothermia/pethidine group. These errors occurred blinded 
to treatment group allocation. A total of 56 animals were therefore included in the analysis of neurobehavioral 
score.” [48] 
3) “Fig 1. Flow chart showing the experimental protocol with the number of animals used, died and included in the 
study…. After baseline CMR and echocardiography, MI was induced by left anterior descending (LAD) coronary 
artery ligation (n = 48), as previously described. As control of surgery procedure, sham operated mice underwent 
thoracotomy and pericardiotomy without coronary artery ligation (n = 12).”[54] 
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3c. For each analysis, report the exact value of N in each experimental group.  
Explanation  
The exact number of experimental units analysed in each group (i.e. the N number) is essential information for the 
reader to interpret the analysis, it should be reported unambiguously. All animals and data used in the experiment 
should be accounted for in the data presented. Sometimes, for good reasons, animals may need to be excluded 
from a study (e.g. illness or mortality), and data points excluded from analyses (e.g. biologically implausible 
values). Reporting losses will help the reader to understand the experimental design process, replicate methods, 
and provide adequate tracking of animal numbers in a study, especially when sample size numbers in the analyses 
do not match the original group numbers.  
Indicate numbers clearly within the text or on figures, and provide absolute numbers (e.g. 10/20, not 50%). For 
studies where animals are measured at different time points, explicitly report the full description of which animals 
undergo measurement, and when [32].  
Examples 
1) “Group F contained 29 adult males and 58 adult females in 2010 (n = 87), and 32 adult males and 66 adult 
females in 2011 (n = 98). The increase in female numbers was due to maturation of juveniles to adults. Females 
belonged to three matrilines, and there were no major shifts in rank in the male hierarchy. Six mid to low ranking 
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individuals died and were excluded from analyses, as were five mid-ranking males who emigrated from the group 
at the beginning of 2011.” [55] 
2) “The proportion of test time that animals spent interacting with the handler (sniffed the gloved hand or tunnel, 
made paw contact, climbed on, or entered the handling tunnel) was measured from DVD recordings. This was 
then averaged across the two mice in each cage as they were tested together and their behaviour was not 
independent…. Mice handled with the home cage tunnel spent a much greater proportion of the test interacting 
with the handler (mean ± s.e.m., 39.8 ± 5.2 percent time of 60 s test, n = 8 cages) than those handled by tail (6.4 ± 
2.0 percent time, n = 8 cages), while those handled by cupping showed intermediate levels of voluntary interaction 
(27.6 ± 7.1 percent time, n = 8 cages).”  [56] 
 
Item 4. Randomisation 
Describe the methods used: 
4a. To allocate experimental units to control and treatment groups. If randomisation was used, provide 
the method of randomisation. 
Explanation 
Using randomisation during the allocation to groups ensures that each experimental unit has an equal probability of 
receiving a particular treatment. It helps minimise selection bias and reduce systematic differences in the 
characteristics of animals allocated to different groups [57-59]. However, investigators frequently confuse “random” 
with “haphazard” or “arbitrary” allocation. Non-random allocation can introduce bias that influences the results, as a 
researcher may (consciously or subconsciously) make judgements in allocating an animal to a particular group, or 
because of unknown and uncontrolled differences in the experimental conditions or animals in different groups. 
Systematic reviews have shown that animal experiments that do not report randomisation or other bias-reducing 
measures such as blinding, are more likely to report exaggerated effects that meet conventional measures of 
statistical significance [60, 61]. It is especially important to use methods of randomisation in situations where it is 
not possible to blind all or parts of the experiment but even with randomisation, researcher bias can pervert the 
allocation. This can be avoided by using allocation concealment (see item 5 – Blinding). In studies where sample 
sizes are small, simple randomisation may result in unbalanced groups; here randomisation strategies to balance 
groups such as randomising in matched pairs [62-64] and blocking are encouraged [24]. 
Report the type of randomisation used (simple, stratified, randomised complete blocks, etc.; see Box 4), the 
method of randomisation (e.g. computer-generated randomisation sequence, with details of the algorithm or 
programme used), and what was randomised (e.g. treatment to experimental unit, order of treatment for each 
animal). The EDA has a dedicated feature for randomisation and allocation concealment [18].  
Examples  
1) “Fifty 12-week-old male Sprague-Dawley rats, weighing 320–360g, were obtained from Guangdong Medical 
Laboratory Animal Center (Guangzhou, China) and randomly divided into two groups (25 rats/group): the intact 
group and the castration group. Random numbers were generated using the standard = RAND() function in 
Microsoft Excel.” [65]  
2) “Animals were randomized after surviving the initial I/R, using a computer based random order generator.” [66] 
3) “At each institute, phenotyping data from both sexes is collected at regular intervals on age-matched wildtype 
mice of equivalent genetic backgrounds. Cohorts of at least seven homozygote mice of each sex per pipeline were 
generated…. The random allocation of mice to experimental group (wildtype versus knockout) was driven by 
Mendelian Inheritance.” [28] 
 
4b. To minimise potential confounding factors such as the order of treatments and measurements, or 
animal/cage location. 
Explanation 
under a CC0 license. 
author/funder. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use 
The copyright holder for this preprint (which was not peer-reviewed) is the. https://doi.org/10.1101/703355doi: bioRxiv preprint 
 12 
Ensuring there is no systematic difference between animals in different groups apart from the experimental 
exposure is an important principle throughout the conduct of the experiment. Identifying nuisance variables 
(sources of variability or conditions that could potentially bias results), and managing them in the design of the 
experiment increases the sensitivity of the experiment. For example, rodents in cages at the top of the rack may be 
exposed to higher light levels, which can affect stress [67]. Mitigation strategies for nuisance variables include 
randomising or counterbalancing the position of animal cages on the rack, and taking measurements or processing 
samples in a random order (preferably with the investigator blinded to the treatment received; see item 5 – 
Blinding). Such practices help avoid introducing unintentional systematic differences between comparison groups, 
also known as order effects. Strategies to avoid order effects include counterbalancing, randomising order of 
treatment, and blocking (see Box 4).  
Box 4: Considerations for randomisation   
Simple randomisation 
All animals/samples are simultaneously randomised to the treatment groups without considering any other 
variable. This strategy is rarely appropriate as it cannot ensure that comparison groups are balanced for factors 
or covariates that might influence the result of an experiment. 
Randomisation within blocks  
Blocking is a method of controlling natural variation among experimental units. This splits up the experiment into 
smaller sub-experiments (blocks), and treatments are randomised to experimental units within each block [24, 
68, 69]. This takes into account nuisance variables that could potentially bias the results (e.g. cage location, day 
or week of procedure). 
Stratified randomisation uses the same principle as randomisation within blocks, only the strata tend to be traits 
of the animal that are likely to be associated with the response (e.g. weight class or tumour size class). This can 
lead to differences in the practical implementation of stratified randomisation as compared to block 
randomisation (e.g. there may not be equal numbers of experimental units in each weight class). 
Other randomisation techniques 
Minimisation is an alternative strategy to allocate animals/samples to treatment group to balance confounding 
variables that might influence the result of an experiment. With minimisation the treatment allocated to the next 
animal/sample depends on the characteristics of those animals/samples already assigned. The aim is that each 
allocation should minimise the imbalance across multiple factors [70]. This approach works well for a continuous 
nuisance variable such as body weight or starting tumour volume. 
Examples of nuisance variables that can be accounted for in the randomisation strategy 
▪ Time or day of the experiment  
▪ Litter, cage or fish tank 
▪ Investigator or surgeon – different level of experience in the people administering the treatments, performing 
the surgeries, or assessing the results may result in varying stress levels in the animals or duration of 
anaesthesia 
▪ Equipment (e.g. PCR machine, spectrophotometer) – calibration may vary 
▪ Measurement of a study parameter (e.g. initial tumour volume) 
▪ Animal characteristics – sex, age class, weight class 
▪ Location – exposure to light, ventilation and disturbances may vary in cages located at different height or on 
different racks, which may affect important physiological processes 
Implication for the analysis  
If blocking factors are used in the randomisation, they should also be included in the analysis. Nuisance 
variables increase variability in the sample, which reduces statistical power. Including a nuisance variable as a 
blocking factor in the analysis accounts for that variability and can increase the power, thus increasing the ability 
to detect a real effect with fewer experimental units. However, blocking uses up degrees of freedom and thus 
reduces the power if the nuisance variable does not have a substantial impact on variability. 
 
Report the methods used to minimise confounding factors alongside the methods used to allocate animals to 
groups. 
Examples  
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1) “Randomisation was carried out as follows. On arrival from El-Nile Company, animals were assigned a group 
designation and weighed. A total number of 32 animals were divided into four different weight groups (eight 
animals per group). Each animal was assigned a temporary random number within the weight range group. On the 
basis of their position on the rack, cages were given a numerical designation. For each group, a cage was 
selected randomly from the pool of all cages. Two animals were removed from each weight range group and given 
their permanent numerical designation in the cages. Then, the cages were randomized within the exposure 
group.” [71] 
2) ”...test time was between 08.30am to 12.30pm and testing order was randomized daily, with each animal tested 
at a different time each test day.” [72] 
3) “Bulls were blocked by BW into four blocks of 905 animals with similar BW and then within each block, bulls 
were randomly assigned to one of four experimental treatments in a completely randomized block design resulting 
in 905 animals per treatment. Animals were allocated to 20 pens (181 animals per pen and five pens per 
treatment).” [73] 
 
Item 5. Blinding 
Describe who was aware of the group allocation at the different stages of the experiment (during the 
allocation, the conduct of the experiment, the outcome assessment, and the data analysis). 
Explanation  
Researchers often expect a particular outcome, and can unintentionally influence the experiment or interpret the 
data in such a way as to support their preferred hypothesis [74]. Blinding is a strategy used to minimise these 
subjective biases.  
Whilst there is primary evidence of the impact of blinding in the clinical literature that directly compares blinded vs 
unblinded assessment of outcomes [75], there is limited empirical evidence in animal research [76, 77]. There are, 
however, compelling data from systematic reviews showing that non-blinded outcome assessment leads to the 
treatment effects being overestimated, and the lack of bias-reducing measures such as randomisation and blinding 
can contribute to as much as 30-45% inflation of effect sizes [60, 78, 79]. 
Ideally, investigators should be unaware of the treatment(s) animals have received or will be receiving, from the 
start of the experiment until the data have been analysed. If this is not possible for all the stages of an experiment 
(see Box 5), it should always be possible to conduct at least some of the stages blind. This has implications for the 
organisation of the experiment and may require help from additional personnel, for example a surgeon to perform 
interventions, a technician to code the treatment syringes for each animal, or a colleague to code the treatment 
groups for the analysis. Online resources are available to facilitate allocation concealment and blinding [18]. 
Box 5: Blinding during different stages of an experiment 
During allocation 
Allocation concealment refers to concealing the treatment to be allocated to each individual animal from those 
assigning the animals to groups, until the time of assignment. Together with randomisation, allocation 
concealment helps minimise selection bias, which can introduce systematic differences between treatment 
groups.  
During the conduct of the experiment 
Where possible, animal care staff and those who administer treatments should be unaware of allocation groups 
to ensure that all animals in the experiment are handled, monitored and treated in the same way. Treating 
different groups differently based on the treatment they have received could alter animal behaviour and 
physiology, and produce confounds.  
Welfare or safety reasons may prevent blinding of animal care staff but in most cases, blinding is possible. For 
example, if hazardous microorganisms are used, control animals can be considered as dangerous as infected 
animals. If a welfare issue would only be tolerated for a short time in treated but not control animals, a harm-
benefit analysis is needed to decide whether blinding should be used. 
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During the outcome assessment 
The person collecting experimental measurements or conducting assessments should not know which treatment 
each sample/animal received, and which samples/animals are grouped together. Blinding is especially important 
during outcome assessment, particularly if there is a subjective element (e.g. when assessing behavioural 
changes or reading histological slides) [76]. Randomising the order of examination can also reduce bias. 
If the person assessing the outcome cannot be blinded to the group allocation (e.g. obvious phenotypic or 
behavioural differences between groups) some, but not all, of the sources of bias could be mitigated by sending 
data for analysis to a third party, who has no vested interest in the experiment and does not know whether a 
treatment is expected to improve or worsen the outcome.  
During the data analysis 
The person analysing the data should know which data are grouped together to enable group comparisons, but 
should not be aware of which treatment each group received. This type of blinding is often neglected, but is 
important as the analyst makes many semi-subjective decisions such as applying data transformation to 
outcome measures, choosing methods for handling missing data and handling outliers. How these decisions will 
be made should also be decided a priori. 
Data can be coded prior to analysis so that the treatment group cannot be identified before analysis is 
completed. 
 
Specify whether blinding was used or not for each step of the experimental process (see Box 5). If blinding was not 
possible during a specific stage of the experiment, provide the reason why. 
Examples 
1) “For each animal, four different investigators were involved as follows: a first investigator (RB) administered the 
treatment based on the randomization table. This investigator was the only person aware of the treatment group 
allocation. A second investigator (SC) was responsible for the anaesthetic procedure, whereas a third investigator 
(MS, PG, IT) performed the surgical procedure. Finally, a fourth investigator (MAD) (also unaware of treatment) 
assessed GCPS and NRS, MNT, and sedation NRS scores.” [80] 
2) “…due to overt behavioral seizure activity the experimenter could not be blinded to whether the animal was 
injected with pilocarpine or with saline.” [81] 
3) “Investigators could not be blinded to the mouse strain due to the difference in coat colors, but the three-
chamber sociability test was performed with ANY-maze video tracking software (Stoelting, Wood Dale, IL, USA) 
using an overhead video camera system to automate behavioral testing and provide unbiased data analyses. The 
one-chamber social interaction test requires manual scoring and was analyzed by an individual with no knowledge 
of the questions.” [82] 
 
Item 6. Outcome measures 
6a. Clearly define all outcome measures assessed (e.g. cell death, molecular markers, or behavioural 
changes).  
Explanation 
An outcome measure (also known as a dependent variable or a response variable) is any variable recorded during 
a study (e.g. volume of damaged tissue, number of dead cells, specific molecular marker) to assess the effects of a 
treatment or experimental intervention. Outcome measures may be important for characterising a sample (e.g. 
baseline data) or for describing complex responses (e.g. ‘haemodynamic’ outcome measures including heart rate, 
blood pressure, central venous pressure, and cardiac output).  
Explicitly describe what was measured, especially when measures can be operationalised in different ways. For 
example, activity could be recorded as time spent moving or distance travelled. Where possible, the recording of 
outcome measures should be made in an unbiased manner (e.g. blinded to the treatment allocation of each 
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experimental group; see item 5 – Blinding). Specify how the outcome measure(s) assessed are relevant to the 
objectives of the study. 
Example 
1) “The following parameters were assessed: threshold pressure (TP; intravesical pressure immediately before 
micturition); post-void pressure (PVP; intravesical pressure immediately after micturition); peak pressure (PP; 
highest intravesical pressure during micturition); capacity (CP; volume of saline needed to induce the first 
micturition); compliance (CO; CP to TP ratio); frequency of voiding contractions (VC) and frequency of non-voiding 
contractions (NVCs).” [83] 
 
6b. For hypothesis-testing studies, specify the primary outcome measure, i.e. the outcome measure that 
was used to determine the sample size. 
Explanation 
In a hypothesis-testing experiment, the primary outcome measure answers the main biological question. It is the 
outcome of greatest importance, identified in the planning stages of the experiment and used as the basis for the 
sample size calculation (see Box 3). For exploratory studies it is not necessary to identify a single primary outcome 
and often multiple outcomes are assessed (see item 13 – Objectives).  
In a hypothesis-testing study powered to detect an effect on the primary outcome measure, data on secondary 
outcomes are used to evaluate additional effects of the intervention but subsequent statistical analysis of 
secondary outcome measures may be underpowered, making results and interpretation less reliable [84, 85]. 
Studies that claim to test a hypothesis but do not specify a pre-defined primary outcome measure, or those that 
change the primary outcome measure after data were collected (also known as primary outcome switching) are 
liable to selectively report only statistically significant results, favouring more positive findings [86].  
Registering a protocol in advance protects the researcher against concerns about selective outcome reporting (also 
known as data dredging or p-hacking) and provides evidence that the primary outcome reported in the manuscript 
accurately reflects what was planned [87] (see item 19 – Protocol registration).  
If the study was designed to test a hypothesis and more than one outcome was assessed, explicitly identify the 
primary outcome measure and state if it was defined as such prior to data collection.  
Examples  
1) “The primary outcome of this study will be forelimb function assessed with the staircase test. Secondary 
outcomes constitute Rotarod performance, stroke volume (quantified on MR imaging or brain sections, 
respectively), diffusion tensor imaging (DTI) connectome mapping, and histological analyses to measure neuronal 
and microglial densities, and phagocytic activity… The study is designed with 80% power to detect a relative 25% 
difference in pellet-reaching performance in the Staircase test.” [88] 
2. “The primary endpoint of this study was defined as left ventricular ejection fraction (EF) at the end of follow-up, 
measured by magnetic resonance imaging (MRI). Secondary endpoints were left ventricular end diastolic volume 
and left ventricular end systolic volume (EDV and ESV) measured by MRI, infarct size measured by ex vivo gross 
macroscopy after incubation with triphenyltetrazolium chloride (TTC) and late gadolinium enhancement (LGE) 
MRI, functional parameters serially measured by pressure volume (PV-)loop and echocardiography, coronary 
microvascular function by intracoronary pressure- and flow measurements and vascular density and fibrosis on 
histology. Based on a power calculation (estimated effect 7.5% [6], standard deviation of 5%, a power of 0.9 and 
alpha of 0.05) 8 pigs per group were needed.” [66] 
 
Item 7. Statistical methods 
7a. Provide details of the statistical methods used for each analysis. 
Explanation 
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In hypothesis-testing studies comparing two or more groups, inferential statistics are used to estimate the size of 
the effect and to determine the weight of evidence against the null hypothesis. The effect size is the magnitude of 
the difference between two groups. The description of the statistical analysis should provide enough detail so that 
another researcher could re-analyse the raw data using the same method and obtain the same results. Relevant 
information includes what the outcome measures and independent variables were, what statistical analyses were 
performed, what tests were used to check assumptions, and any data transformations [89]. Give details of any 
confounders, blocking factors or covariates taken into account for each statistical test, include how the effects of 
each were mitigated. This allows readers to assess if analysis methods were appropriate.  
In exploratory studies where no specific hypothesis was tested, descriptive statistics can be used to summarise the 
data (see item 10 – Results). They do not allow conclusions beyond the data but are important for generating new 
hypotheses that may be tested in subsequent experiments.  
For any study reporting descriptive statistics, explicitly state which measure of central tendency is reported (e.g. 
mean or median) and which measure of variability is reported (e.g. standard deviation, range, quartiles or 
interquartile range). 
Examples 
1) “Analysis of variance was performed using the GLM procedure of SAS (SAS Inst., Cary, NC). Average pen 
values were used as the experimental unit for the performance parameters. The model considered the effects of 
block and dietary treatment (5 diets). Data were adjusted by the covariant of initial body weight. Orthogonal 
contrasts were used to test the effects of SDPP processing (UV vs no UV) and dietary SDPP level (3% vs 6%). 
Results are presented as least squares means. The level of significance was set at P < 0.05.” [90] 
2) ”All risk factors of interest were investigated in a single model. Logistic regression allows blocking factors and 
explicitly investigates the effect of each independent variable controlling for the effects of all others.... As we were 
interested in husbandry and environmental effects, we blocked the analysis by important biological variables (age; 
backstrain; inbreeding; sex; breeding status) to control for their effect. (The role of these biological variables in 
barbering behavior, particularly with reference to barbering as a model for the human disorder trichotillomania, is 
described elsewhere: Garner et al., 2004). We also blocked by room to control for the effect of unknown 
environmental variables associated with this design variable. We tested for the effect of the following husbandry 
and environmental risk factors: cage mate relationships (i.e. siblings, non-siblings, or mixed); cage type (i.e. plastic 
or steel); cage height from floor; cage horizontal position (whether the cage was on the side or the middle of a 
rack); stocking density; and the number of adults in the cage. Cage material by cage height from floor; and cage 
material by cage horizontal position interactions were examined, and then removed from the model as they were 
nonsignificant. N = 1959 mice were included in this analysis” [91] 
 
7b. Specify the experimental unit that was used for each statistical test.  
Explanation  
Incorrect identification of the experimental unit can lead to pseudoreplication and underpowered studies (see item 
1 – Study design). For example, measurements from 50 individual cells from a single mouse represent N = 1 
when the experimental unit is the mouse. The 50 measurements are subsamples and provide an estimate of 
measurement error so should be averaged or used in a nested analysis. Reporting N = 50 in this case is an 
example of pseudoreplication [22]. It underestimates the true variability in a study, which can lead to false positives. 
If, however, each cell taken from the mouse is then randomly allocated to different treatments and assessed 
individually, the cell might be regarded as the experimental unit.  
Explicitly report the experimental unit used in each statistical analysis. 
Examples  
1) “For each test, the experimental unit was an individual animal.” [92] 
2) “Maternal data regarding body weight, food intake, water consumption, urinary cotinine level and hormonal 
analysis were analyzed using the individual animal as the experimental unit. The data for offspring regarding body 
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weight, food intake, organ weight at necropsy, urinary cotinine level, immunohistochemical cellular distribution, 
TUNEL+ cells, RT-PCR and hormonal analysis were analyzed using the litter as the experimental unit.” [93] 
 
7c. Describe any methods used to assess whether the data met the assumptions of the statistical 
approach. 
Explanation  
Hypothesis tests are based on assumptions about the underlying data. Describing how assumptions were 
assessed, and whether these assumptions are met by the data, enables readers to assess the suitability of the 
statistical approach used. If the assumptions are incorrect, the conclusions may not be valid. For example, the 
assumptions for data used in parametric tests (such as a t-test, Z-test, ANOVA, Pearson’s r coefficient, etc.) are 
that the data are continuous, the residuals from the analysis are normally distributed, the responses are 
independent, and that different groups should have similar variances.  
There are various tests for normality, for example the Shapiro-Wilk and Kolmogorov-Smirnov tests. However, these 
tests have to be used cautiously. If the sample size is small, they will struggle to detect non-normality, if the sample 
size is large, the tests will detect minor deviations. An alternative approach is to evaluate data with visual plots e.g. 
normal probability plots, box plots, scatterplots. If the residuals of the analysis are not normally distributed, the 
assumption may be satisfied using a data transformation where the same mathematical function is applied to all 
data points to produce normally distributed data (e.g. loge, log10, square root, arcsine).  
Other types of outcome measures (binary, categorical, or ordinal) will require different methods of analysis, and 
each will have different sets of assumptions. For example, categorical data are summarised by counts and 
percentages or proportions, and are analysed by tests of proportions; these analysis methods assume that data are 
binary, ordinal or nominal, and independent [94].  
Report the type of outcome measure and the methods used to test the assumptions of the statistical approach. If 
data were transformed, identify precisely the transformation used and which outcome measures it was applied to.  
Examples 
1) “Model assumptions were checked using the Shapiro-Wilk normality test and Levene’s Test for homogeneity of 
variance and by visual inspection of residual and fitted value plots. Some of the response variables had to be 
transformed by applying the natural logarithm or the second or third root, but were back-transformed for 
visualization of significant effects.” [95] 
2) The effects of housing (treatment) and day of euthanasia on cortisol levels were assessed by using fixed-effects 
2-way ANOVA. An initial exploratory analysis indicated that groups with higher average cortisol levels also had 
greater variation in this response variable. To make the variation more uniform, we used a logarithmic transform of 
each fish's cortisol per unit weight as the dependent variable in our analyses. This action made the assumptions of 
normality and homoscedasticity (standard deviations were equal) of our analyses reasonable. [96]  
 
Item 8. Experimental animals 
8a. Provide details of the animals used, including species, strain and substrain, sex, age or 
developmental stage, and weight. 
Explanation 
The species, strain, substrain, sex, weight, and age of animals are critical factors that can influence most 
experimental results [97-101]. Reporting the characteristics of all animals used is equivalent to standardised human 
patient demographic data; these data support both the internal and external validity of the study results. It enables 
other researchers to repeat the experiment and generalise the findings. It also enables readers to assess whether 
the animal characteristics chosen for the experiment are relevant to the research objectives.  
under a CC0 license. 
author/funder. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use 
The copyright holder for this preprint (which was not peer-reviewed) is the. https://doi.org/10.1101/703355doi: bioRxiv preprint 
 18 
Report age and weight for each group, include summary statistics (e.g. mean and standard deviation) and, if 
possible, baseline values for individual animals (e.g. as supplementary information or a link to a publicly accessible 
data repository). For most species, precise reporting of age is more informative than a description of the 
developmental status (e.g. a mouse referred to as an adult can vary in age from six to 20 weeks [102]). In some 
cases, however, reporting the developmental stage is more informative than chronological age, for example in 
juvenile Xenopus, where rate of development can be manipulated by incubation temperature [103]. 
Example 
1) “One hundred and nineteen male mice were used: C57BL/6OlaHsd mice (n = 59), and BALB/c OlaHsd mice (n 
= 60) (both from Harlan, Horst, The Netherlands). At the time of the EPM test the mice were 13 weeks old and had 
body weights of 27.4 ± 0.4 g and 27.8 ± 0.3 g, respectively (mean ± SEM).” [104] 
2) “Histone Methylation Profiles and the Transcriptome of X. tropicalis Gastrula Embryos. To generate epigenetic 
profiles, ChIP was performed using specific antibodies against trimethylated H3K4 and H3K27 in Xenopus 
gastrula-stage embryos (Nieuwkoop-Faber stage 11–12), followed by deep sequencing (ChIP-seq). In addition, 
polyA-selected RNA (stages 10–13) was reverse transcribed and sequenced (RNA-seq).” [105] 
 
8b. Provide further relevant information on the provenance of animals, health/immune status, genetic 
modification status, genotype, and any previous procedures. 
Explanation 
The animals’ provenance, their health or immune status and their history of previous testing or procedures, can 
influence their physiology and behaviour as well as their response to treatments, and thus impact on study 
outcomes. For example, animals of the same strain, but from different sources, or animals obtained from the same 
source but at different times, may be genetically different [17]. The immune or microbiological status of the animals 
can also influence welfare, experimental variability and scientific outcomes [106-108]. 
Report the health status of animals in the study, and any previous procedures the animals have undergone. For 
genetically modified animals, describe the genetic modification status (e.g. knockout, overexpression), genotype 
(e.g. homozygous, heterozygous), manipulated gene(s), genetic methods and technologies used to generate the 
animals, how the genetic modification was confirmed, and details of animals used as controls (e.g. littermate 
controls [109]).  
Reporting the correct nomenclature is crucial to understanding the data and ensuring that the research is 
discoverable and replicable [110-112]. Useful resources for reporting nomenclature for different species include:  
▪ Mice - International Committee on Standardized Genetic Nomenclature (https://www.jax.org/jax-mice-and-
services/customer-support/technical-support/genetics-and-nomenclature)  
▪ Rats - Rat Genome and Nomenclature Committee (https://rgd.mcw.edu/) 
▪ Zebrafish - Zebrafish Information Network (http://zfin.org/) 
▪ Xenopus - Xenbase (http://www.xenbase.org/entry/) 
▪ Drosophila – FlyBase (http://flybase.org/)  
Examples 
1) “A construct was engineered for knockin of the miR-128 (miR-128-3p) gene into the Rosa26 locus. Rosa26 
genomic DNA fragments (~1.1 kb and ~4.3 kb 5′ and 3′ homology arms, respectively) were amplified from 
C57BL/6 BAC DNA, cloned into the pBasicLNeoL vector sequentially by in-fusion cloning, and confirmed by 
sequencing. The miR-128 gene, under the control of tetO-minimum promoter, was also cloned into the vector 
between the two homology arms. In addition, the targeting construct also contained a loxP sites flanking the 
neomycin resistance gene cassette for positive selection and a diphtheria toxin A (DTA) cassette for negative 
selection. The construct was linearized with ClaI and electroporated into C57BL/6N ES cells. After G418 selection, 
seven-positive clones were identified from 121 G418-resistant clones by PCR screening. Six-positive clones were 
expanded and further analyzed by Southern blot analysis, among which four clones were confirmed with correct 
targeting with single-copy integration. Correctly targeted ES cell clones were injected into blastocysts, and the 
blastocysts were implanted into pseudo-pregnant mice to generate chimeras by Cyagen Biosciences Inc. Chimeric 
males were bred with Cre deleted mice from Jackson Laboratories to generate neomycin-free knockin mice. The 
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correct insertion of the miR-128 cassette and successful removal of the neomycin cassette were confirmed by 
PCR analysis with the primers listed in Supplementary Table 1.” [113] 
2) “The C57BL/6J (Jackson) mice were supplied by Charles River Laboratories. The C57BL/6JOlaHsd (Harlan) 
mice were supplied by Harlan. The α-synuclein knockout mice were kindly supplied by Prof. [X] (Cardiff University, 
Cardiff, United Kingdom.) and were congenic C57BL/6JCrl (backcrossed for 12 generations). TNFα−/− mice were 
kindly supplied by Dr. [Y] (Queens University, Belfast, Northern Ireland) and were inbred on a homozygous 
C57BL/6J strain originally sourced from Bantin & Kingman and generated by targeting C57BL/6 ES cells. T286A 
mice were obtained from Prof. [Z] (University of California, Los Angeles, CA). These mice were originally congenic 
C57BL/6J (backcrossed for five generations) and were then inbred (cousin matings) over 14 y, during which time 
they were outbred with C57BL/6JOlaHsd mice on three separate occasions.” [114] 
 
Item 9. Experimental procedures 
For each experimental group, including controls, describe the procedures in enough detail to allow 
others to replicate them, including:  
9a. What was done, how it was done and what was used. 
Explanation 
Essential information to describe in the manuscript includes the procedures used to develop the model (e.g. 
induction of the pathology), the procedures used to measure the outcomes, and pre- and post-experimental 
procedures, including animal handling and welfare monitoring. Animal handling can be a source of stress and the 
specific method used (e.g. mice picked up by tail or in cupped hands) can affect research outcomes [56, 115, 116]. 
Details about animal care and monitoring intrinsic to the procedure are discussed in further detail in item 16 – 
Animal care and monitoring. Provide enough detail to enable others to replicate the methods and highlight any 
quality assurance and quality control used [117, 118]. A schematic of the experimental procedures with a timeline 
can give a clear overview of how the study was conducted. Information relevant to distinct types of interventions 
and resources are described in Box 6.  
Box 6: Examples of information to include when reporting specific types experimental procedures and 
resources 
Procedures Resources 
Pharmacological procedures (intervention and control) 




▪ Site and route of administration 
▪ Frequency of administration 
▪ Vehicle or carrier solution formulation and volume 
▪ Any evidence that the pharmacological agent used 
reaches the target tissue 
Surgical procedures (including sham surgery) 
▪ Description of the surgical procedure 
▪ Anaesthetic used (including dose and other 
information listed in pharmacological procedures 
section above) 
▪ Pre and post analgesia regimen 
▪ Pre-surgery procedures (e.g. fasting) 
▪ Aseptic techniques 




▪ Provenance  
▪ Verification and authentication 
▪ RRID [120, 121] 
Reagents (e.g. antibodies, chemicals) 
▪ Manufacturer 
▪ Supplier 
▪ Catalogue number 
▪ Lot number (if applicable) 
▪ RRID 
Equipment and software 
▪ Manufacturer 
▪ Supplier 
▪ Model/version number 
▪ Calibration procedures (if applicable) 
▪ RRID 
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▪ Whether the procedure is terminal or not 
▪ Post-surgery procedures 
▪ Duration of the procedure and duration of 
anaesthesia 
▪ Physical variables measured 
Pathogen infection (intervention and control) 
▪ Infectious agent 
▪ Dose load 
▪ Vehicle or carrier solution formulation and volume 
▪ Site and route of infection 
▪ Timing or frequency of infection 
Euthanasia 
▪ Method of euthanasia, including the humane 
standards the method complies with, such as 
AVMA [119] 
▪ Pharmacological agent, if used (including dose 
and information listed in pharmacological 
procedures section above) 
▪ Any measures taken to reduce pain and distress 
before or during euthanasia 
▪ Timing of euthanasia 
▪ Tissues collected post-euthanasia and timing of 
collection 
 
Where available, cite the Research Resource Identifier (RRID) for reagents and tools used [120, 121]. RRIDs are 
unique and stable, allowing unambiguous identification of reagents or tools used in a study, aiding other 
researchers to replicate the methods.  
Detailed step-by-step procedures can also be saved and shared online, for example using Protocols.io [122], which 
assigns a DOI to the protocol and allows cross-referencing between protocols and publications. 
Examples 
1) “Fig… shows the timeline for instrumentation, stabilization, shock/injury, and resuscitation…. Animals were 
food-deprived for 18 hours before surgery, but allowed free access to water. On the morning of surgery, swine 
were sedated with tiletamine-zolazepam (Telazol®; 5-8 mg/kg IM; Zoetis Inc., Kalamazoo MI) in the holding pen, 
weighed, and masked with isoflurane (3%, balance 100% O2) for transport to the lab. The marginal ear vein was 
catheterized for administration of atropine (0.02 mg/kg IV; Sparhawk Laboratories, Lenexa KS), and 
buprenorphine for pre-emptive analgesia (3 mg/ml IV; ZooPharm, Laramie WY). Ophthalmic ointment (Puralube®; 
Fera Pharmaceuticals) was applied to prevent corneal drying. Animals were intubated in dorsal recumbency with a 
cuffed 6 or 7 Fr endotracheal tube. Anesthetic plane was maintained by isoflurane (1-1.5%; 21-23 % O2, balance 
N2). Oxygen saturation (sPO2, %) and heart rate (HR) were monitored with a veterinary pulse oximeter placed in 
the buccal cavity (Masimo SET Radical-7; Irvine CA). Core temperature was monitored with a rectal probe and 
maintained at 36.5-38oC with a microprocessor-controlled feedback water blanket (Blanketrol® II, Cincinnati Sub-
Zero (CSZ) Cincinnati, OH) placed under the animal. Anesthetic depth was assessed every 5 min for the duration 
of the experiment by reflexes (corneal touch, pedal flexion, coronary band pinch) and vital signs (sPO2, HR, core 
temperature). 
Fig.... Experimental time line for instrumentation, shock/injury, resuscitation, post-resuscitation monitoring, and 
blood sampling in a swine model of polytrauma and coagulopathy.” [123] 
2) “For the diet-induced obesity (DIO) model, eight-week-old male mice had ad libitum access to drinking water 
and were kept on standard chow (SFD, 10.9 kJ/g) or on western high-fat diet (HFD; 22 kJ/g; kcal from 42% fat, 
43% from carbohydrates and 15% from protein; E15721-34, Ssniff, Soest, Germany) for 15 weeks 
(http://dx.doi.org/10.17504/protocols.io.kbacsie).” [124] 
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9b. When and how often. 
Explanation 
Clearly report the frequency and timing of experimental procedures and measurements, including the light and dark 
cycle (e.g. 12:12), circadian time cues (e.g. lights on at 08:00), and experimental time sequence (e.g. interval 
between baseline and comparator measurements or interval between procedures and measurements). Along with 
innate circadian rhythms, these can affect research outcomes such as behavioural, physiological, and 
immunological parameters [125, 126]. Also report the timing and frequency of welfare assessments, taking into 
consideration the normal activity patterns (see item 16 – Animal care and monitoring). For example, nocturnal 
animals may not show behavioural signs of discomfort during the day [127]. 
Examples 
1) “Blood pressure, heart rate, oxygen saturation and amount of blood extracted were recorded every 5 minutes. 
Blood samples were drawn at baseline (pre injury), 0 minutes (immediately after injury), and after 30 and 60 
minutes.” [128] 
2) “After a 5-h fast (7:30–12:30am), awake and freely moving mice were randomized and subjected to three 
consecutive clamps performed in the same mice as described above, with a 2 days recovery after each 
hyperinsulinemic/hypoglycemic (mHypo, n = 6) or hyperinsulinemic/euglycemic (mEugly, n = 4) clamps.” [129] 
 
9c. Where (including detail of any acclimation periods). 
Explanation 
Physiological acclimation after a stressful event, such as transport (e.g. between supplier, animal facility and 
laboratory), but before the experiment begins allows stabilisation of physiological responses of the animal [130, 
131]. Protocols vary depending on species, strain, and outcome; for example physiological acclimation following 
transportation of different animals can take anywhere from 24 hours to more than one week [132]. Procedural 
acclimation, immediately before a procedure, allows stabilisation of the animals’ responses after unaccustomed 
handling, novel environments, and previous procedures, which otherwise can induce behavioural and physiological 
changes [133, 134]. 
Indicate where studies were performed (e.g. dedicated laboratory space or animal facility, home cage, open field 
arena, water maze) and whether periods of physiological or procedural acclimation were included in the study 
protocol, including type and duration. If the study involved multiple sites explicitly state where each experiment and 
sample analysis was performed. Include any accreditation of laboratories if appropriate (e.g. if samples are sent to 
a commercial laboratory for analysis).  
Example 
1) “Fish were singly housed for 1 week before being habituated to the conditioning tank over 2 consecutive days. 
The conditioning tank consisted of an opaque tank measuring 20 cm (w) 15 cm (h) 30 cm (l) containing 2.5 l of 
aquarium water with distinct visual cues (spots or stripes) on walls at each end of the tank… During habituation, 
each individual fish was placed in the conditioning apparatus for 20 minutes with free access to both 
compartments and then returned to its home tank.” [135] 
 
9d. Why (provide rationale for procedures). 
Explanation 
There may be numerous approaches to investigate any given research problem, therefore it is important to explain 
why a particular procedure or technique was chosen. This is especially relevant when procedures are novel or 
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specific to a research laboratory, or constrained by the animal model or experimental equipment (e.g. route of 
administration determined by animal size [136]). 
Examples 
1) “Because of the very small caliber of the murine tail veins, partial paravenous injection is common if 18F-FDG is 
administered by tail vein injection (intravenous). This could have significantly biased our comparison of the 
biodistribution of 18F-FDG under various conditions. Therefore, we used intraperitoneal injection of 18F-FDG for 
our experiments evaluating the influence of animal handling on 18F-FDG biodistribution.” [137] 
2)“Since Xenopus oocytes have a higher potential for homologous recombination than fertilized embryos 
(Hagmann et al., 1996), we next tested whether the host transfer method could be used for efficient HDR-
mediated knock-in.  We targeted the C-terminus of X. laevis Ctnnb1 (β-catenin), a key cytoskeletal protein and 
effector of the canonical Wnt pathway, because previous studies have shown that addition of epitope tags to the 
C-terminus do not affect the function of the resulting fusion protein (Fig. 2A) (Evans et al., 2010; Miller and Moon, 
1997). CRISPR components were injected into X. laevis oocytes followed by host transfer or into embryos.” [138] 
 
Item 10. Results 
For each experiment conducted, including independent replications, report:  
10a. Summary/descriptive statistics for each experimental group, with a measure of variability where 
applicable. 
Explanation 
Summary/descriptive statistics provide a quick and simple description of the data, they communicate quantitative 
results easily and facilitate visual presentation. For continuous data, these descriptors include a measure of central 
tendency (e.g. mean, median) and a measure of variability (e.g. quartiles, range, standard deviation) to help 
readers assess the precision of the data collected. Categorical data can be expressed as counts, frequencies, or 
proportions.  
Report data for all experiments conducted. If a complete experiment is repeated on a different day, or under 
different conditions, report the results of all repeats, rather than selecting data from representative experiments. 
Report the exact number of experimental units per group so readers can gauge reliability of results (see item 2 – 
Sample size, and item 3 – Inclusion and exclusion criteria). Present data clearly as text, in tables, or in graphs, 
to enable information to be evaluated, or extracted for future meta-analyses. Report descriptive statistics with a 
clearly identified measure of variability for each group. Example 1 shows data summarised as medians and, in 
brackets, lower and upper quartiles. Boxplots are a convenient way to summarise continuous data, plotted as 
median, interquartile range, minimum, maximum and outliers, as shown in Example 2. 
 Examples 
1) “Features of autism compared between the control group and the autistic model groups” [139] 
 Median (quartiles)  
 Control group (n=13) Autism model group (n=14)  
Birth weight (g) 
Weight at 28 weeks (g) 
Number of squares traversed 
Rearing movements 
Grooming movements (number of rats performing 
grooming movements/total in the group) 
4.2 (3.9 – 4.5) 
47.8 (44.0 – 51.8) 
6.0 (4.0 – 11.0) 
6.0 (4.0 – 13.0) 
4/13 
3.6 (2.9 – 5.0) 
32.5 (29.0 – 53.5) 
3.0 (2.0 – 7.0) 
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2) “Boxplots of median heart rate (beats per minute, bpm) during rs-fMRI scans for Y (n = 12), AU (n = 12), and AI 
(n = 12) animals.”[140] 
 
 
10b. If applicable, the effect size with a confidence interval.  
Explanation  
An effect size is a quantitative measure that estimates the magnitude of differences between groups, or 
relationships between variables. It can be used to assess the patterns in the data collected and make inferences 
about the wider population from which the sample came. The confidence interval for the effect indicates how 
precisely the effect has been estimated, and tells the reader about the strength of the effect [141]. For example, if 
zero is included in the 95% confidence interval, the presence of an effect cannot be assumed. In studies where 
statistical power is low, and/or hypothesis-testing is inappropriate, providing the effect size and confidence interval 
indicates how small or large an effect might really be, so a reader can judge the biological significance of the data 
[142, 143]. Reporting effect sizes with confidence intervals also facilitates extraction of useful data for systematic 
review and meta-analysis. Where multiple independent studies included in a meta-analysis show quantitatively 
similar effects, even if each is statistically non-significant, this provides powerful evidence that a relationship is 
‘real’, although small. 
Report all analyses performed, even those providing non-statistically significant results. Report the effect size, to 
indicate the size of the difference between groups in the study, with a confidence interval, to indicate the precision 
of the effect size estimate.  
Example 
1) “For all traits identified as having a significant genotype effect for the Usp47tm1b(EUCOMM)Wtsi line 
(MGI:5605792), a comparison is presented of the standardized genotype effect with 95% confidence interval for 
each sex with no multiple comparisons correction. Standardization, to allow comparison across variables, was 
achieved by dividing the genotype estimate by the signal seen in the wildtype population. Shown in red are 
statistically significant estimates. RBC: red blood cells; BMC: bone mineral content; BMD: bone mineral density; 
WBC: white blood cells.” [28] 
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2. Recommended Set 
The Recommended Set (Box 7) adds context to the study described, including further detail about the methodology 
and advice on what to include in the more narrative parts of a manuscript. Items are presented in a logical order, 
there is no ranking within the set. 




14. Ethical statement 
15. Housing and husbandry 
16. Animal care and monitoring 
17. Interpretation /scientific implications 
18. Generalisability /translation 
19. Protocol registration 
20. Data access 
21. Declaration of interests 
 
Item 11. Abstract  
Provide an accurate summary of the research objectives, animal species, strain and sex, key methods, 
principal findings, and study conclusions.  
Explanation  
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A transparent and accurate abstract increases the utility and impact of the manuscript, and allows readers to 
assess the reliability of the study [144]. The abstract is often used as a screening tool by readers to decide whether 
to read the full article or to select an article for inclusion in a systematic review. However, abstracts often either do 
not contain enough information for this purpose [145, 146], or contain information that is inconsistent with the 
results in the rest of the manuscript [147, 148].  
To maximise utility, include details of the species, sex and strain of animals used, and accurately report the 
methods, results and conclusions of the study.  Also describe the objectives of the study, including whether it was 
designed to either test a specific hypothesis or to generate a new hypothesis (see Item 13 – Objectives). 
Incorporating this information will enable readers to interpret the strength of evidence, and judge how the study fits 
within the wider knowledge base. 
Examples 
1) “BACKGROUND AND PURPOSE: Asthma is an inflammatory disease that involves airway 
hyperresponsiveness and remodelling. Flavonoids have been associated to anti-inflammatory and antioxidant 
activities and may represent a potential therapeutic treatment of asthma. Our aim was to evaluate the effects of 
the sakuranetin treatment in several aspects of experimental asthma model in mice. 
EXPERIMENTAL APPROACH: Male BALB/c mice received ovalbumin (i.p.) on days 0 and 14, and were 
challenged with aerolized ovalbumin 1% on days 24, 26 and 28. Ovalbumin-sensitized animals received vehicle 
(saline and dimethyl sulfoxide, DMSO), sakuranetin (20 mg kg–1per mice) or dexamethasone (5 mg kg–1 per 
mice) daily beginning from 24th to29th day. Control group received saline inhalation and nasal drop vehicle. On 
day 29, we determined the airway hyperresponsiveness, inflammation and remodelling as well as specific IgE 
antibody. RANTES, IL-5, IL-4, Eotaxin, IL-10, TNF-a, IFN-g and GMC-SF content in lung homogenate was 
performed by Bioplex assay, and 8-isoprostane and NF-kB activations were visualized in inflammatory cells by 
immunohistochemistry. 
KEY RESULTS: We have demonstrated that sakuranetin treatment attenuated airway hyperresponsiveness, 
inflammation and remodelling; and these effects could be attributed to Th2 pro-inflammatory cytokines and 
oxidative stress reduction as well as control of NF-kB activation. 
CONCLUSIONS AND IMPLICATIONS: These results highlighted the importance of counteracting oxidative stress 
by flavonoids in this asthma model and suggest sakuranetin as a potential candidate for studies of treatment of 
asthma.” [149] 
2) “In some parts of the world, the laboratory pig (Sus scrofa) is often housed in individual, sterile housing which 
may impose stress. Our objectives were to determine the effects of isolation and enrichment on pigs housed within 
the PigTurn® — a novel penning system with automated blood sampling — and to investigate tear staining as a 
novel welfare indicator. Twenty Yorkshire × Landrace weaner pigs were randomly assigned to one of four 
treatments in a 2 × 2 factorial combination of enrichment (non-enriched [NE] or enriched [E]) and isolation (visually 
isolated [I] or able to see another pig [NI]). Pigs were catheterised and placed into the PigTurns® 48 h post 
recovery. Blood was collected automatically twice daily to determine white blood cell (WBC) differential counts and 
assayed for cortisol. Photographs of the eyes were taken daily and tear staining was quantified using a 0–5 
scoring scale and Image-J software to measure stain area and perimeter. Behaviour was video recorded and scan 
sampled to determine time budgets. Data were analysed as an REML using the MIXED procedure of SAS. 
Enrichment tended to increase proportion of time standing and lying laterally and decrease plasma cortisol, tear-
stain area and perimeter. There was a significant isolation by enrichment interaction. Enrichment given to pigs 
housed in isolation had no effect on plasma cortisol, but greatly reduced it in non-isolated pigs. Tear-staining area 
and perimeter were highest in the NE-I treatment compared to the other three treatments. Eosinophil count was 
highest in the E-NI treatment and lowest in the NE-I treatment. The results suggest that in the absence of 
enrichment, being able to see another animal but not interact may be frustrating. The combination of no 
enrichment and isolation maximally impacted tear staining and eosinophil numbers. However, appropriate 
enrichment coupled with proximity of another pig would appear to improve welfare.” [150] 
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Item 12. Background  
12a. Include sufficient scientific background to understand the rationale and context for the study, and 
explain the experimental approach. 
Explanation  
Scientific background information for an animal study should demonstrate a clear evidence gap and explain why an 
in vivo approach was warranted. Systematic reviews of the animal literature provide the most convincing evidence 
that a research question has not been conclusively addressed, by showing the extent of current evidence within a 
field of research. They can also inform the choice of animal model by providing a comprehensive overview of the 
models used along with their benefits and limitations [151, 152].  
Describe the rationale and context of the study and how it relates to other research, including relevant references 
to previous work. Outline evidence underpinning the hypothesis or objectives and explain why the experimental 
approach is best suited to answer the research question. 
Example 
1) “For decades, cardiovascular disease has remained the leading cause of mortality worldwide ...[and] 
cardiovascular research has been performed using healthy and young, non-diseased animal models. Recent 
failures of cardioprotective therapies in obese insulin-resistant, diabetic, metabolic syndrome-affected and aged 
animals that were otherwise successful in healthy animal models has highlighted the need for the development of 
animal models of disease that are representative of human clinical conditions… In the clinical setting, elderly male 
patients often present with both testosterone deficiency (TD) and the metabolic syndrome (MetS). A strong and 
compounding association exists between MetS and TD which may have significant impact on cardiovascular 
disease and its outcomes which is not addressed by current models…. their mutual presentation in the clinical 
setting warrants the development of appropriate animal models of the MetS with hypogonadism, especially in the 
context of cardiovascular disease research.” [153] 
 
12b. Explain how the animal species and model used address the scientific objectives and, where 
appropriate, the relevance to human biology. 
Explanation 
Provide enough detail for the reader to assess the suitability of the animal model used to address the research 
question. Include information on the rationale for choosing a particular species, explain how the outcome measures 
assessed are relevant to the condition under study, and how the model was validated. Stating that an animal model 
is commonly used in the field is not appropriate, and a well-considered, detailed rationale should be provided.  
When the study models a human disease, indicate how the model is appropriate for addressing the specific 
objectives of the study  [154]. This can include a description of how the induction of the disease, disorder, or injury 
is sufficiently analogous to the human condition, how the model responds to known clinically-effective treatments, 
how similar symptoms are to the clinical disease and how animal characteristics were selected to represent the 
age, sex, and health status of the clinical population [14].  
Examples 
1) “… we selected a pilocarpine model of epilepsy that is characterized by robust, frequent spontaneous 
seizures acquired after a brain insult, well-described behavioral abnormalities, and poor responses to 
antiepileptic drugs. These animals recapitulate several key features of human temporal lobe epilepsy, the most 
common type of epilepsy in adults.” [155] 
2) “Transplantation of healthy haematopoietic stem cells (HSCs) is a critical therapy for a wide range of 
malignant haematological and non-malignant disorders and immune dysfunction (Snowden et al., 2012; Sykes & 
Nikolic, 2005; Thomas et al., 1957)…. Zebrafish are already established as a successful model to study the 
haematopoietic system, with significant homology with mammals (de Jong & Zon, 2005; Gering & Patient, 2005; 
Kissa & Herbomel, 2010; Renshaw & Trede, 2012; Traver et al., 2003; White et al., 2008). Imaging of zebrafish 
transparent embryos remains a powerful tool and has been critical to confirm that the zebrafish Caudal 
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Haematopoietic Tissue (CHT) is comparable to the mammalian foetal haematopoietic niche (Gering & Patient, 
2005; Kissa & Herbomel, 2010; Tamplin et al., 2015). Xenotransplantation in zebrafish embryos has revealed 
highly conserved mechanisms between zebrafish and mammals. Recently, murine bone marrow cells were 
successfully transplanted into zebrafish embryos, revealing highly conserved mechanism of haematopoiesis 
between zebrafish and mammals (Parada-Kusz et al., 2017). Additionally, CD34 enriched human cells 
transplanted into zebrafish were shown to home to the CHT and respond to zebrafish stromal-cell derived factors 
(Staal et al., 2016).” [156] 
 
Item 13. Objectives 
Clearly describe the research question, research objectives and, where appropriate, specific hypotheses 
being tested.  
Explanation  
Explaining the purpose of the study by describing the question(s) that the research addresses, allows readers to 
determine if the study is relevant to them. Readers can also assess the relevance of the model organism, 
procedures, outcomes measured, and analysis used.  
Knowing if a study is exploratory or hypothesis-testing is critical to its interpretation. A typical exploratory study may 
measure multiple outcomes and look for patterns in the data, or relationships that can be used to generate 
hypotheses. It may also be a pilot study which aims to inform the design or feasibility of larger subsequent 
experiments. Exploratory research helps researchers to design hypothesis-testing experiments, by choosing what 
variables or outcome measures to focus on in subsequent studies. 
Testing a specific hypothesis has implications for both the study design and the data analysis [17, 157]. For 
example, an experiment designed to detect a hypothesised effect will likely need to be analysed with inferential 
statistics, and a statistical estimation of the sample size will need to be performed a priori (see item 2 – Sample 
size). Hypothesis-testing studies also have a pre-defined primary outcome measure, which is used to assess the 
evidence in support of the specific research question (see item 6 – Outcome measures).  
In contrast, exploratory research investigates many possible effects, and is likely to yield more false positive results 
because some will be positive by chance; thus results from well-designed hypothesis-testing studies provide 
stronger evidence. Independent replication and meta-analysis can further increase the confidence in conclusions. 
Clearly outline the objective(s) of the study, including whether it is hypothesis-testing or exploratory, or if it includes 
research of both types. Hypothesis-testing studies may collect additional information for exploratory purposes, it is 
important to distinguish which hypotheses were prespecified and which originated after data inspection, especially 
when reporting unanticipated effects or outcomes that were not part of the original study design. 
Examples 
1) “The primary objective of this study was to investigate the cellular immune response to MSC injected into the 
striatum of allogeneic recipients (6-hydroxydopamine [6-OHDA]-hemilesioned rats, an animal model of Parkinson's 
disease [PD]), and the secondary objective was to determine the ability of these cells to prevent nigrostriatal 
dopamine depletion and associated motor deficits in these animals.” [158] 
2) “In this exploratory study, we aimed to investigate whether calcium electroporation could initiate an anticancer 
immune response similar to electrochemotherapy. To this end, we treated immunocompetent balb/c mice with 
CT26 colon tumors with calcium electroporation, electrochemotherapy, or ultrasound-based delivery of calcium or 
bleomycin.” [159] 
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Item 14. Ethical statement 
Provide the name of the ethical review committee or equivalent that has approved the use of animals in 
this study and any relevant licence or protocol numbers (if applicable). If ethical approval was not sought 
or granted, provide a justification. 
Explanation 
Authors are responsible for complying with regulations and guidelines relating to the use of animals for scientific 
purposes. This includes ensuring that they have the relevant approval for their study from an appropriate ethics 
committee and/or regulatory body before the work starts. The ethical statement provides editors, reviewers and 
readers with assurance that studies have received this ethical oversight [12]. This also promotes transparency and 
understanding about the use of animals in research and fosters public trust.  
Provide a clear statement explaining how the study conforms to appropriate regulations and guidelines, and 
indicate relevant licence/protocol numbers so that the study can be identified. Add also any relevant accreditation 
e.g. AAALAC (American Association for Accreditation of Laboratory Animal Care) [160] or GLP (Good Laboratory 
Practice). 
If the research is not covered by any regulation and formal ethical approval is not required (e.g. a study using 
animal species not protected by regulations or law), demonstrate that international standards were complied with 
and cite the appropriate reference. In such cases, provide a clear statement explaining why the research is exempt 
from regulatory approval.  
Examples  
1) “All procedures were conducted in accordance with the United Kingdom Animal (Scientific Procedures) Act 
1986, approved by institutional ethical review committees (Alderley Park Animal Welfare and Ethical Review 
Board and Babraham Institute Animal Welfare and Ethical Review Board) and conducted under the authority of 
the Project Licence (40/3729 and 70/8307, respectively).” [161] 
2) “All protocols in this study were approved by the Committee on the Ethics of Animal Experiments of Fuwai 
Hospital, Peking Union Medical College and the Beijing Council on Animal Care, Beijing, China (IACUC permit 
number: FW2010-101523), in compliance with the Guide for the Care and Use of Laboratory Animals published by 
the US National Institutes of Health (NIH publication no.85-23, revised 1996).” [162] 
3) “Samples and data were collected according to Institut de Sélection d’Animale (ISA) protocols, under the 
supervision of ISA employees. Samples and data were collected as part of routine animal data collection in a 
commercial breeding program for layer chickens in The Netherlands. Samples and data were collected on a 
breeding nucleus of ISA for breeding purposes only, and is a non-experimental, agricultural practice, regulated by 
the Act Animals, and the Royal Decree on Procedures. The Dutch Experiments on Animals Act does not apply to 
non-experimental, agricultural practices. An ethical review by the Statement Animal Experiment Committee was 
therefore not required. No extra animal discomfort was caused for sample collection for the purpose of this study.” 
[163] 
 
Item 15. Housing and husbandry 
Provide details of housing and husbandry conditions, including any environmental enrichment. 
Explanation 
The environment determines the health and wellbeing of the animals and every aspect of it can potentially affect 
their behavioural and physiological responses, thereby affecting research outcomes. Different studies may be 
sensitive to different environmental factors, and particular aspects of the environment necessary to report may 
depend on the type of study. Examples of housing and husbandry conditions known to affect animal welfare and 
research outcomes are listed in Table 1; consider reporting these elements and any other housing and husbandry 
conditions likely to influence the study outcomes. 
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Table 1: Examples of information to consider when reporting housing and husbandry, and their effects 
on laboratory animals 
Information to report Examples of effects on laboratory animals 
Cage/housing system (type 
and dimensions) 
Affects behaviour [164] and fear learning [165]. Tank colour affects stress in 
Xenopus laevis [166]. 
Food and water (type, 
composition and access) 
Affects body weight, tumour development, nephropathy severity [167], and  the 
threshold for developing Parkinsonian symptoms [168]. Maternal diet affects 
offspring body weight [169]. 
Bedding and nesting material Affects behavioural responses to stress [170] and pain [171]. 
Temperature and humidity Modifies tumour progression [172]. 
Sanitation (frequency of cage 
changes, material transferred) 
Affects blood pressure, heart rate, behaviour [173]. Adds an additional source 
of variation [174, 175]. 
Social environment (group size 
and composition) 
Compromises animal welfare [176]. Induces aggressive behaviour [177]. 
Biosecurity (level) The microbiological status of animals causes variation in systemic disease 
parameters [178]. 
Lighting (type, schedule and 
intensity) 
Modifies immune and stress responses[179]. 
Environmental enrichment 
 
Reduces anxiety [180, 181], stress [180, 181] and abnormal repetitive 
behaviour [182-184]. Reduces susceptibility to epilepsy [185] and osteoarthritis 
[186] and modifies the pathology of neurological disorders [187]. 
Sex of the experimenter Affects physiological stress and pain behaviour [188]. 
 
Environment, either deprived or enriched, can affect a wide range of physiological and behavioural responses 
[189]. Specific details to report include, but are not limited to, structural enrichment (e.g. elevated surfaces, 
dividers), resources for species-typical activities (e.g. nesting material, shelters, gnawing sticks), toys and or other 
tools used to stimulate exploration, exercise (e.g. running wheel), and novelty. If no environmental enrichment was 
provided, this should be clearly stated with justification. Similarly, scientific justification needs to be reported for 
withholding food and water [190], and for singly housing animals [191, 192]. 
Examples 
1) “Breeding colonies were kept in individually ventilated cages (IVCs; Tecniplast, Italy) at a temperature of 20°C 
to 24°C, humidity of 50% to 60%, 60 air exchanges per hour in the cages, and a 12/12-hour light/dark cycle with 
the lights on at 5:30 AM. The maximum caging density was five mice from the same litter and sex starting from 
weaning. As bedding, spruce wood shavings (Lignocel FS-14; J. Rettenmaier und Soehne GmbH, Rosenberg, 
Germany) were provided. Mice were fed a standardized mouse diet (1314, Altromin, Germany) and provided 
drinking water ad libitum. All materials, including IVCs, lids, feeders, bottles, bedding, and water were autoclaved 
before use. Sentinel mice were negative for at least all Federation of laboratory animal science associations 
(FELASA)-relevant murine infectious agents [30] as diagnosed by our health monitoring laboratory, mfd 
Diagnostics GmbH, Wendelsheim, Germany.” [193] 
2) “Same sex litter mates were housed together in individually ventilated cages with two or four mice per cage. All 
mice were maintained on a regular diurnal lighting cycle (12:12 light:dark) with ad libitum access to food (7012 
Harlan Teklad LM-485 Mouse/Rat Sterilizable Diet) and water. Chopped corn cob was used as bedding. 
Environmental enrichment included nesting material (Nestlets, Ancare, Bellmore, NY, USA), PVC pipe, and shelter 
(Refuge XKA-2450-087, Ketchum Manufacturing Inc., Brockville, Ontario, Canada). Mice were housed under 
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broken barrier-specific pathogen-free conditions in the Transgenic Mouse Core Facility of Cornell University, 
accredited by AAALAC (The Association for Assessment and Accreditation of Laboratory Animal Care 
International).” [194] 
 
Item 16. Animal care and monitoring 
16a. Describe any interventions or steps taken in the experimental protocols to reduce pain, suffering 
and distress. 
Explanation 
A safe and effective analgesic plan is critical to relieve pain, suffering and distress. Untreated pain can affect the 
animals’ biology and add variability to the experiment; however specific pain management procedures can also 
introduce variability, affecting experimental data [195, 196]. Under-reporting of welfare management procedures 
can also contribute to the perpetuation of non-compliant methodologies and insufficient or inappropriate use of 
analgesia [196] or other welfare measures. A thorough description of the procedures used to alleviate pain, 
suffering and distress provides practical information for researchers to replicate the method. 
Clearly describe pain management strategies, including: 
▪ specific analgesic 
▪ administration method (formulation, route, dose, concentration, volume, frequency, timing, and equipment 
used) 
▪ rationale for the choice (e.g. animal model, disease/pathology, procedure, mechanism of action, 
pharmacokinetics, personnel safety) 
▪ protocol modifications to reduce pain, suffering and distress (e.g. changes to the anaesthetic protocol, 
increased frequency of monitoring, procedural modifications, habituation, etc.) 
If analgesics or other welfare measures, reasonably expected for the procedure performed, are not performed for 
experimental reasons, report the scientific justification [197].  
Examples 
1) “If piglets developed diarrhea, they were placed on an electrolyte solution and provided supplemental water, 
and if the diarrhea did not resolve within 48 h, piglets received a single dose of ceftiofur (5.0 mg ceftiofur 
equivalent/kg of body weight i.m [Excede, Zoetis, Florham Park, NJ]). If fluid loss continued after treatment, piglets 
then received a single dose of sulfamethoxazole and trimethoprim oral suspension (50 mg/8 mg per mL, Hi-Tech 
Pharmacal, Amityville, NY) for 3 consecutive days.” [198] 
2) “One hour before surgery, we administered analgesia to the mice by offering them nut paste (Nutella; Ferrero, 
Pino Torinese, Italy) containing 1 mg per kg body weight buprenorphine (Temgesic; Schering-Plough Europe, 
Brussels, Belgium) for voluntary ingestion, as described previously. The mice had been habituated to pure nut 
paste for 2 d prior to surgery.” [199] 
3) “If a GCPS score equal or greater than 6 (out of 24) was assigned postoperatively, additional analgesia was 
provided with methadone 0.1 mg kg−1 IM (or IV if required), and pain reassessed 30 minutes later. The number of 
methadone doses was recorded.” [44] 
 
16b. Report any expected or unexpected adverse events. 
Explanation 
Reporting adverse events allows other researchers to minimise the risk of these events occurring in their own 
studies and to plan appropriate welfare assessments. If the experiment is testing the efficacy of a treatment, the 
occurrence of adverse events may alter the balance between treatment benefit and risk [33].  
Report any adverse events, expected or unexpected, that had a negative impact on the welfare of the animals in 
the study (e.g. cardiovascular and respiratory depression, CNS disturbance, hypothermia, reduction of food intake). 
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Examples 
1) “Murine lymph node tumors arose in 11 of 12 mice that received N2-transduced human cells. The neo gene 
could be detected in murine cells as well as in human cells. Significant lymphoproliferation could be seen only in 
the murine pre-T cells. It took 5 months for murine leukemia to arise; the affected mice displayed symptoms of 
extreme sickness rapidly, with 5 of the 12 mice becoming moribund on exactly the same day (Figure 3), and 6 
others becoming moribund within a 1-month period…Of the 12 mice that had received N2-transduced human 
cells, 11 had to be killed because they developed visibly enlarged lymph nodes and spleen, hunching, and 
decrease in body weight, as shown in Figure 3….The 12th mouse was observed carefully for 14 months; it did not 
show any signs of leukemia or other adverse events, and had no abnormal tissues when it was autopsied.…The 
mice were observed at least once daily for signs of illness, which were defined as any one or more of the 
following: weight loss, hunching, lethargy, rapid breathing, skin discoloration or irregularities, bloating, hemi-
paresis, visibly enlarged lymph nodes, and visible solid tumors under the skin. Any signs of illness were logged as 
“adverse events” in the experiment, the mouse was immediately killed, and an autopsy was performed to establish 
the cause of illness.” [200] 
2) “Although procedures were based on those reported in the literature, dogs under Protocol 1 displayed high 
levels of stress and many experienced vomiting. This led us to significantly alter procedures in order to optimize 
the protocol for the purposes of our own fasting and postprandial metabolic studies.” [201]  
 
16c. Describe the humane endpoints established for the study and the frequency of monitoring. 
Explanation 
Humane endpoints are predetermined morphological, physiological and/or behavioural signs that define the 
circumstances under which an animal will be removed from an experimental study. The use of humane endpoints 
can help minimise harm while allowing the scientific objectives to be achieved [202]. Report the humane endpoints 
that were established for the specific study, species and strain. Include clear criteria of the clinical signs monitored 
[127], and clinical signs that led to euthanasia or other defined actions. Include details such as general welfare 
indicators (e.g. weight loss, reduced food intake, abnormal posture) and procedure-specific welfare indicators (e.g. 
tumour size in cancer studies [47], sensory motor deficits in stroke studies [203]).  
Report the timing and frequency of monitoring, taking into consideration the normal circadian rhythm of the animal 
and timing of scientific procedures, as well as any increase in the frequency of monitoring (e.g. post-surgery 
recovery, critical times during disease studies, or following the observation of an adverse event). Publishing score 
sheets of the clinical signs that were monitored [204] can help guide other researchers to develop clinically relevant 
welfare assessments, particularly for studies reporting novel procedures.  
Example 
1) “Both the research team and the veterinary staff monitored animals twice daily. Health was monitored by weight 
(twice weekly), food and water intake, and general assessment of animal activity, panting, and fur condition…. The 
maximum size the tumors allowed to grow in the mice before euthanasia was 2000 mm3.” [205] 
 
Item 17. Interpretation/scientific implications 
17a. Interpret the results, taking into account the study objectives and hypotheses, current theory and 
other relevant studies in the literature. 
Explanation 
It is important to interpret the results of the study in the context of the study objectives (see item 13 – Objectives). 
For hypothesis-testing studies, interpretations should be restricted to the primary outcome (see item 6 – Outcome 
measures). Exploratory results derived from additional outcomes should not be described as conclusive, as they 
may be underpowered and less reliable. 
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Discuss the findings in the context of current theory, ideally with reference to a relevant systematic review, as 
individual studies do not provide a complete picture. If a systematic review is not available, take care to avoid 
selectively citing studies that corroborate the results, or only those that report statistically significant findings [206].  
Where appropriate, describe any implications of the experimental methods or research findings for improving 
welfare standards or reducing the number of animals used in future studies (e.g. the use of a novel approach 
reduced the results’ variability, thus enabling the use of smaller group sizes without losing statistical power). This 
may not be the primary focus of the research but reporting this information enables wider dissemination and uptake 
of refined techniques within the scientific community.  
Examples  
1) “This is in contrast to data provided by an ‘intra-renal IL-18 overexpression’ model [43], and may reflect an IL-18 
concentration exceeding the physiologic range in the latter study.” [207] 
2) “The new apparatus shows potential for considerably reducing the number of animals used in memory tasks 
designed to detect potential amnesic properties of new drugs ... approximately 43,000 animals have been used in 
these tasks in the past 5 years but with the application of the continual trials apparatus we estimate that this could 
have been reduced to 26,000…. with the new paradigm the number of animals needed to obtain reliable results 
and maintain the statistical power of the tasks is greatly reduced.” [208] 
3) “In summary, our results show that IL-1Ra protects against brain injury and reduces neuroinflammation when 
administered peripherally to aged and comorbid animals at reperfusion or 3 hours later. These findings address 
concerns raised in a recent systematic review on IL-1Ra in stroke [209], and provide further supporting evidence 
for IL-1Ra as a lead candidate for the treatment of ischemic stroke.” [210] 
 
17b. Comment on the study limitations including potential sources of bias, limitations of the animal 
model, and imprecision associated with the results. 
Explanation 
Discussing the limitations of the work is important to place the findings in context, interpret the validity of the 
results, and ascribe a credibility level to its conclusions [211]. Limitations are unavoidable in scientific research, and 
describing them is essential to share experience, guide best practice, and aid the design of future experiments.  
Discuss the quality of evidence presented in the study, and consider how appropriate the animal model is to the 
specific research question. A discussion on the rigour of the study design to isolate cause and effect (also known 
as internal validity [212]) should include whether potential risks of bias have been addressed [9]. 
Examples 
1) “Although in this study we did not sample the source herds, the likelihood of these herds to be Influenza A virus 
(IAV) positive is high given the commonality of IAV infections in the Midwest. However, we cannot fully rule out the 
possibility that new gilts became infected with resident viruses after arrival to the herd. Although new gilts were 
placed into isolated designated areas and procedures were in place to minimize disease transmission (eg. 
isolation, vaccination), these areas or procedures might not have been able to fully contain infections within the 
designated areas.” [213] 
2) “Even though our data demonstrates that sustained systemic TLR9 stimulation aggravates diastolic HF in our 
model of gene-targeted diastolic HF, there are several limitations as to mechanistic explanations of causality, as 
well as extrapolations to clinical inflammatory disease states and other HF conditions. First, our pharmacological 
inflammatory model does not allow discrimination between effects caused by direct cardiac TLR9 stimulation to 
that of indirect effects mediated by systemic inflammation. Second, although several systemic inflammatory 
conditions have disturbances in the innate immune system as important features, and some of these again 
specifically encompassing distorted TLR9 signalling [34], sustained TLR9 stimulation does not necessarily 
represent a clinically relevant inflammatory condition. Finally, the cardiac myocyte SERCA2a KO model does not 
adequately represent the molecular basis for, or the clinical features of, diastolic HF.” [214] 
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Item 18. Generalisability/translation 
Comment on whether, and how, the findings of this study are likely to generalise to other species or 
experimental conditions, including any relevance to human biology (where appropriate). 
Explanation  
An important purpose of publishing research findings is to inform future research. In the context of animal studies, 
this might take the form of further in vivo research or another research domain (e.g. human clinical trial). Thoughtful 
consideration is warranted, as additional unnecessary animal studies are wasteful and unethical. Similarly, human 
clinical trials initiated based on insufficient or misleading animal research evidence increase research waste and 
negatively influence the risk-benefit balance for research participants [212, 215].  
Consider whether the findings may be used to inform future research in a broadly similar context, or whether 
enough evidence has been accumulated in the literature to justify further research in another species or in humans. 
Discuss what (if any) further research may be required to allow generalisation or translation. Discuss and interpret 
the results in relation to current evidence, and in particular whether similar [216] or otherwise supportive [217] 
findings have been reported by other groups. Discuss the range of circumstances in which the effect is observed, 
and factors which may moderate that effect. Such factors could include for example the population (e.g. age, sex, 
strain, species), the intervention (e.g. different drugs of the same class), and the outcome measured (e.g. different 
approaches to assessing memory).   
Examples  
1) “Our results demonstrate that hDBS robustly modulates the mesolimbic network. This finding may hold clinical 
relevance for hippocampal DBS therapy in epilepsy cases, as connectivity in this network has previously been 
shown to be suppressed in mTLE. Further research is necessary to investigate potential DBS-induced restoration 
of MTLE-induced loss of functional connectivity in mesolimbic brain structures.” [218] 
2) “The tumor suppressor effects of GAS1 had been previously reported in cell cultures or in xenograft models, 
this is the first work in which the suppressor activity of murine Gas1 is reported for primary tumors in vivo. Recent 
advances in the design of safe vectors for transgene delivery may result in extrapolating our results to humans 
and so a promising field of research emerges in the area of hepatic, neoplastic diseases.” [219] 
 
Item 19. Protocol registration  
Provide a statement indicating whether a protocol (including the research question, key design features, 
and analysis plan) was prepared before the study, and if and where this protocol was registered. 
Explanation 
Akin to the approach taken for clinical trials, protocol registration has emerged as a mechanism that is likely to 
improve the transparency of animal research [215, 220, 221]. Registering a protocol before the start of the 
experiment enables researchers to demonstrate that the hypothesis, approach and analysis were planned in 
advance and not shaped by data as they emerged; it enhances scientific rigour and protects the researcher against 
concerns about selective reporting of results [222, 223]. A protocol should consist of a) the question being 
addressed and the key features of the research that is proposed, such as the hypothesis being tested and the 
primary outcome measure (if applicable), the statistical analysis plan; and b) the laboratory procedures to be used 
to perform the planned experiment.  
Protocols may be registered with different levels of completeness. For example, in the Registered Report format 
offered by an increasing number of journals, protocols undergo peer review and if accepted, the journal commits to 
publishing the completed research regardless of the results obtained [220]. 
Other online resources include the Open Science Framework [224], which is suitable to deposit PHISPS 
(Population; Hypothesis; Intervention; Statistical Analysis Plan; Primary; Outcome Measure; Sample Size 
Calculation) protocols [225] and provide researchers with the flexibility to embargo the preregistration and keep it 
from public view until the research is published, and selectively share it with reviewers and editors. The EDA can 
also be used to generate a time-stamped PDF, which sets out key elements of the experimental design [18]. This 
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can be used to demonstrate that the study conduct, analysis and reporting were not unduly driven by emerging 
data. As a minimum we recommend registering protocols containing all PHISPS components as outlined above. 
Provide a statement indicating whether or not any protocol was prepared before the study, and if applicable, the 
location of its registration. Where there have been deviations from the protocol, describe the rationale for these 
changes in the publication so that readers can take this into account when assessing the findings. 
Examples 
1) “A detailed description of all protocols can be found in the Registered Report (Kandela et al., 2015). Additional 
detailed experimental notes, data, and analysis are available on the Open Science Framework (OSF) (RRID: 
SCR_003238) (https://osf.io/xu1g2/; Mantis et al., 2016).” [226]  
2 )“To maximise the objectivity of the presented analyses, we preregistered this study with its two hypotheses, its 
planned methods, and its complete plan of data analysis before the start of data collection (https://osf.io/fh8eq/), 
and we closely adhered to our plan… All statistical analyses closely followed our preregistered analysis plan 
(https://osf.io/fh8eq/).” [227] 
3) “We preregistered our analyses with the Open Science Framework which facilitates reproducibility and open 
collaboration in science research (Foster & Deardorff, 2017). Our preregistration: Sheldon and Griffith (2017), was 
carried out to limit the number of analyses conducted and to validate our commitment to testing a limited number 
of a priori hypotheses. Our methods are consistent with this preregistration (Sheldon & Griffith, 2017).” [228]  
 
Item 20. Data access  
Provide a statement describing if and where study data are available. 
Explanation  
A data sharing statement describes how others can access the data on which the paper is based. Sharing 
adequately annotated data allows others to replicate data analyses, so that results can be independently tested 
and verified. Data sharing allows the data to be repurposed and new datasets to be created by combining data 
from multiple studies (e.g. to be used in secondary analyses). This allows others to explore new topics and 
increases the impact of the study, potentially preventing unnecessary use of animals and providing more value for 
money. Access to raw data also facilitates text and automated data mining [229].  
An increasing number of publishers and funding bodies require authors or grant holders to make their data publicly 
available [230]. Journal articles with accompanying data may be cited more frequently [231]. Datasets can also be 
independently cited in their own right, which provides additional credit for authors. This practice is gaining 
increasing recognition and acceptance [232].   
Where possible, make available all data that contribute to summary estimates or claims presented in the paper. 
Data should follow the FAIR guiding principles [233], that is data are findable, accessible (i.e. don’t use outdated 
file types), interoperable (can be used on multiple platforms and with multiple software packages) and re-usable 
(i.e. have adequate data descriptors).  
Data can be made publicly available via a structured, specialised (domain-specific), open access repository such 
as those maintained by NCBI (https://www.ncbi.nlm.nih.gov/) or EBI (https://www.ebi.ac.uk/). If such a repository is 
not available, data can be deposited in unstructured but publicly available repositories (e.g. Figshare 
(https://figshare.com/), Dryad (https://datadryad.org/), Zenodo (https://zenodo.org/) or Open Science Framework 
(https://osf.io/)). There are also search platforms to identify relevant repositories with rigorous standards (e.g. 
FairSharing (https://fairsharing.org/) and re3data (https://www.re3data.org/). 
Examples 
1) “Data Availability Statement: All data are available from Figshare at 
http://dx.doi.org/10.6084/m9.figshare.1288935.” [234] 
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2) “A fundamental goal in generating this dataset is to facilitate access to spiny mouse transcript sequence 
information for external collaborators and researchers. The sequence reads and metadata are available from the 
NCBI (PRJNA342864) and assembled transcriptomes (Trinity_v2.3.2 and tr2aacds_v2) are available from the 
Zenodo repository (https://doi.org/10.5281/zenodo.808870), however accessing and utilizing this data can be 
challenging for researchers lacking bioinformatics expertise. To address this problem we are hosting a 
SequenceServer32 BLAST-search website 
(http://spinymouse.erc.monash.edu/sequenceserver/http://spinymouse.erc.monash.edu/sequenceserver/). This 
resource provides a user-friendly interface to access sequence information from the tr2aacds_v2 assembly (to 
explore annotated protein-coding transcripts) and/or the Trinity_v2.3.2 assembly (to explore non-coding 
transcripts).” [235] 
 
Item 21. Declaration of interests 
21a. Declare any potential conflicts of interest, including financial and non-financial. If none exist, this 
should be stated. 
Explanation 
A competing or conflict of interest is anything that interferes with (or could be perceived as interfering with) the full 
and objective presentation, analysis, and interpretation of the research. Competing or conflicts of interest can be 
financial or non-financial, professional or personal. They can exist in institutions, in teams, or with individuals. 
Potential competing interests are considered in peer review, editorial and publication decisions; the aim is to 
ensure transparency, and in most cases, a declaration of a conflict of interest does not obstruct the publication or 
review process. 
Examples are provided in Box 8. If unsure, declare all potential conflicts, including both perceived and real conflicts 
of interest [236]. 
Box 8: Examples of competing or conflicts of interest 
Financial:  
Funding and other payments received or expected by the authors directly arising from the 
publication of the study, or funding or other payments from an organisation with an interest in the 
outcome of the work.  
Non-financial:  
Research that may benefit the individual or institution in terms of goods in kind. This includes 
unpaid advisory position in a government, non-government organisation or commercial 
organisations. 
Affiliations:  
Employed by, on the advisory board or a member of an organisation with an interest in the outcome 
of the work. 
Intellectual property:  
Patents or trademarks owned by someone or their organisation. This also includes the potential 
exploitation of the scientific advance being reported for the institution, the authors, or the research 
funders. 
Personal:  
Friends, family, relationships, and other close personal connections to people who may potentially 
benefit financially or in other ways from the research.  
Ideology:  
Beliefs or activism (e.g. political or religious) relevant to the work. Membership of a relevant 
advocacy or lobbying organisation. 
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Examples  
1) “The study was funded by Gubra ApS. LSD; PJP ; GH ; KF and HBH are employed by Gubra ApS. JJ and NV 
are the owners of Gubra ApS. Gubra ApS provided support in the form of materials and salaries for authors LSD ; 
PJP ; GH ; KF ; HBH ; JJ and NV.” [237] 
2) “The authors have declared that no competing interests exist.” [238]. 
 
21b. List all funding sources (including grant identifier) and the role of the funder(s) in the design, 
analysis and reporting of the study.  
Explanation 
The identification of funding sources allows the reader to assess any competing interests, and any potential 
sources of bias. For example, bias, as indicated by a prevalence of more favourable outcomes, has been 
demonstrated for clinical research funded by industry compared to studies funded by other sources [239-241]. 
Evidence for preclinical research also indicates that funding sources may influence the interpretation of study 
outcomes [236, 242]. 
Report the funding information including the financial supporting body(s) and any grant identifier(s). Include the role 
of the funder in the design, analysis, reporting and/or or decision to publish. If the research did not receive specific 
funding, but was performed as part of the employment of the authors, name the employer.  
Examples 
1) “Support was provided by the Italian Ministry of Health: Current research funds PRC 2010/001 
[http://www.salute.gov.it/] to MG. The funders had no role in study design, data collection and analysis, decision to 
publish, or preparation of the manuscript.” [243] 
2) “This study was financially supported by the Tuberculosis and Lung Research Center of Tabriz University of 
Medical Sciences and the Research Council of University of Tabriz. The funders had no role in study design, data 
collection and analysis, decision to publish, or preparation of the manuscript.” [244] 
3) “This work was supported by the salary paid to AEW. The funder had no role in study design, data collection 
and analysis, decision to publish, or preparation of the manuscript.” [245] 
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